[go: up one dir, main page]

WO2008103353A1 - Composés de triazole modulant l'activité de hsp90 - Google Patents

Composés de triazole modulant l'activité de hsp90 Download PDF

Info

Publication number
WO2008103353A1
WO2008103353A1 PCT/US2008/002185 US2008002185W WO2008103353A1 WO 2008103353 A1 WO2008103353 A1 WO 2008103353A1 US 2008002185 W US2008002185 W US 2008002185W WO 2008103353 A1 WO2008103353 A1 WO 2008103353A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
independently
sch
och
occurrence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/002185
Other languages
English (en)
Inventor
Weiwen Ying
Teresa Przewloka
Dinesh U. Chimmanamada
Shijie Zhang
Stefan M. Schweizer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of WO2008103353A1 publication Critical patent/WO2008103353A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Definitions

  • chemotherapeutic agents act on a specific molecular target thought to be involved in the development of the malignant phenotype.
  • HSPs Heat shock proteins
  • client proteins cellular proteins
  • the Hsp90 family is one of the most abundant HSP families, accounting for about 1- 2% of proteins in a cell that is not under stress and increasing to about 4-6% in a cell under stress. Inhibition of Hsp90 results in degradation of its client proteins via the ubiquitin proteasome pathway. Unlike other chaperone proteins, the client proteins of Hsp90 are mostly protein kinases or transcription factors involved in signal transduction, and a number of its client proteins have been shown to be involved in the progression of cancer. Examples of Hsp90 client proteins that have been implicated in the progression of cancer are described below.
  • Her-2 is a transmembrane tyrosine kinase cell surface growth factor receptor that is expressed in normal epithelial cells.
  • Her2 has an extracellular domain that interacts with extracellular growth factors and an internal tyrosine kinase portion that transmits the external growth signal to the nucleus of the cell.
  • Her2 is overexpressed in a significant proportion of malignancies, such as breast cancer, ovarian cancer, prostate cancer, and gastric cancers, and is typically associated with a poor prognosis.
  • Akt kinase is a serine/threonine kinase which is a downstream effector molecule of phosphoinositide 3-kinase and is involved in protecting the cell from apoptosis. Akt kinase is thought to be involved in the progression of cancer because it stimulates cell proliferation and suppresses apoptosis. Cdk4/cyclin D complexes are involved in phosphorylation of retinoblastoma protein which is an essential step in progression of a cell through the Gl phase of the cell cycle. Disruption of Hsp90 activity has been shown to decrease the half life of newly synthesized Cdk4.
  • Raf-1 is a MAP 3-kinase (MAP3K) which when activated can phosphorylate and acitivate the serine/threonine specific protein kinases ERKl and ERK2.
  • MAP3K MAP 3-kinase
  • Activated ERKs play an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.
  • the transforming protein of Rous sarcoma virus, v-src is a prototype of an oncogene family that induces cellular transformation (i.e., tumorogenesis) by non- regulated kinase activity.
  • Hsp90 has been shown to complex with v-scr and inhibit its degradation.
  • Hsp90 is required to maintain steroid hormone receptors in a conformation capable of binding hormone with high affinity. Inhibition of the action of Hsp90 therefore is expected to be useful in treating hormone-associated malignancies such as breast cancer.
  • p53 is a tumor suppressor protein that causes cell cycle arrest and apoptosis. Mutation of the p53 gene is found in about half of all human cancers making it one of the most common genetic alterations found in cancerous cells. In addition, p53 mutation is associated with a poor prognosis. Wild-type p53 has been shown to interact with Hsp90, but mutated p53 forms a more stable association than wild-type p53 as a result of its misfolded conformations.
  • Hsp90 A stronger interaction with Hsp90 protects the mutated protein form normal proteolytic degradation and prolongs its half-life.
  • inhibition of the stabilizing effect of Hsp90 causes mutant p53 to be degraded and restores the normal transcriptional activity of wild-type p53.
  • Hif-l ⁇ is a hypoxia-inducible transcription factor that is up-regulated under low oxygen conditions. Under normal oxygen conditions Hif-l ⁇ associates with Von Hippel-Lindau (VHL) tumor suppressor protein and is degraded. Low oxygen conditions inhibit this association and allows Hif-l ⁇ to accumulate and complex with Hif-l ⁇ to form an active transcription complex that associates with hypoxia- response elements to activate the transcription of vascular endothelial growth factor (VEGF). Increased Hif-l ⁇ is associated with increased metastasis and a poor prognosis.
  • VHL Von Hippel-Lindau
  • VEGF vascular endothelial growth factor
  • PKs protein tyrosine kinases
  • STKs serine-threonine kinases
  • PKs protein tyrosine kinases
  • STKs serine-threonine kinases
  • Growth factor receptors with PTK activity are known as receptor tyrosine kinases.
  • Receptor tyrosine kinases are a family of tightly regulated enzymes, and the aberrant activation of various members of the family is one of the hallmarks of cancer.
  • the receptor tyrosine kinase family can be divided into subgroups that have similar structural organization and sequence similarity within the kinase domain.
  • Epidermal Growth Factor Receptor is a member of the type 1 subgroup of receptor tyrosine kinase family of growth factor receptors, which play critical roles in cellular growth, differentiation, and survival. Activation of these receptors typically occurs via specific ligand binding which results in hetero- or homodimerization between receptor family members, with subsequent autophosphorylation of the tyrosine kinase domain.
  • Specific ligands which bind to EGFR include epidermal growth factor (EGF), transforming growth factor ⁇
  • TGF ⁇ amphiregulin and some viral growth factors.
  • Activation of EGFR triggers a cascade of intracellular signaling pathways involved in both cellular proliferation (the ras/raf/MAP kinase pathway) and survival (the PD kinase/ Akt pathway).
  • ras/raf/MAP kinase pathway the ras/raf/MAP kinase pathway
  • survival the PD kinase/ Akt pathway.
  • Members of this family, including EGFR and HER2 have been directly implicated in cellular transformation.
  • EGFR Aberrant or overexpression of EGFR has been associated with an adverse prognosis in a number of human cancers, including head and neck, breast, colon, prostate, lung (e.g., NSCLC, adenocarcinoma and squamous lung cancer), ovaries, gastrointestinal cancers (gastric, colon, pancreatic), renal cell cancer, bladder cancer, glioma, gynecological carcinomas, and prostate cancer.
  • overexpression of tumor EGFR has been correlated with both chemoresistance and a poor prognosis (Lei, et al, Anticancer Res. (1999), 79:221-8; Veale, et al, Br. J. Cancer (1993); 68: 162-5, the entire teachings of each of these references are incorporated herein by reference).
  • Gefitinib a chemotherapeutic agent that inhibits the activity of EGFR
  • Gefitinib a chemotherapeutic agent that inhibits the activity of EGFR
  • these mutants displayed two to three times higher activity than wild type EGFR.
  • wild type EGFR was internalized by the cells and down-regulated after 15 minutes, where as mutant EGFR was internalized more slowly and continued to be activated for up to three hours (Lynch, et al., The New England Journal of Medicine (2006), 350:2129-2139, the entire teachings of which are incorporated herein by reference).
  • Gliomas are another type of cancer that is characterized by amplification and/or mutation of the EGFR gene.
  • One of the most common mutations in the EGFR gene is a deletion of exons 2-7 which results in a truncated form of EGFR in which amino acids 6-273 of the extracellular domain are replaced with a single glycine residue.
  • This mutation is called EGFRvIII and is expressed in about half of all glioblastomas.
  • EGFRvIII is unable to bind EGF and TGF ⁇ and has constitutive, ligand-independent tyrosine kinase activity.
  • Hsp90 co-purifies with EGFRvIII indicating that Hsp90 complexes with EGFRvIII.
  • Hsp90 inhibitor geldanamycin a benzoquinone ansamycin antibiotic
  • Hsp90 inhibitor geldanamycin was able to decrease the expression of EGFRvIII indicating that interaction with Hsp90 is essential to maintain high expression levels of EGFRvIII (Lavictoire, et al., Journal of Biological Chemistry (2003), 278(7):5292-5299, the entire teachings of which are incorporated herein by reference).
  • the members of the type III group of receptor tyrosine kinases include platelet-derived growth factor (PDGF) receptors (PDGF receptors alpha and beta), colony-stimulating factor (CSF-I) receptor (CSF-IR, c-Fms), Fms-like tyrosine kinase (FLT3), and stem cell factor receptor (c-kit).
  • PDGF platelet-derived growth factor
  • CSF-I colony-stimulating factor receptor
  • FLT3 Fms-like tyrosine kinase
  • c-kit stem cell factor receptor
  • Hematologic cancers also known as hematologic or hematopoietic malignancies, are cancers of the blood or bone marrow; including leukemia and lymphoma.
  • Acute myelogenous leukemia is a clonal hematopoietic stem cell leukemia that represents about 90% of all acute leukemias in adults with an incidence of 3.9 per 100,000 (See e.g., Lowenberg et al., N. Eng. J. Med. 341: 1051- 62 (1999) and Lopesde Menezes, et al, Clin. Cancer Res. (2005), 11(14):5281-5291, the enter teachings of both references are incorporated by reference).
  • AML blasts express wild type FLT3 and about 25 % to about 35 % express FLT3 kinase receptor mutations which result in constitutively active FLT3.
  • ITDs internal tandem duplications
  • point mutation in the activating loop of the kinase domain Two types of activating mutations have been identified in AML patients: internal tandem duplications (ITDs) and point mutation in the activating loop of the kinase domain.
  • FLT3-ITD mutations in AML patients is indicative of a poor prognosis for survival, and in patients who are in remission, FLT3-ITD mutations are the most significant factor adversely affecting relapse rate with 64% of patients having the mutation relapsing within 5 years (see Current Pharmaceutical Design (2005), 77:3449-3457, the entire teachings of which are incorporated herein by reference).
  • the prognostic significance of FLT3 mutations in clinical studies suggests that FLT3 plays a driving role in AML and may be necessary for the development and maintenance of the disease.
  • MLL Mixed Lineage Leukemia
  • the FLT3-ITD mutation is also present in about 3% of cases of adult myelodysplastic syndrome and some cases of acute lymphocytic leukemia (ALL) ⁇ Current Pharmaceutical Design (2005), 11 :3449-3457).
  • ALL acute lymphocytic leukemia
  • FLT3 has been shown to be a client protein of Hsp90, and 17AAG, a benzoquinone ansamycin antibiotic that inhibits Hsp90 activity, has been shown to disrupt the association of Flt3 with Hsp90.
  • 17AAG a benzoquinone ansamycin antibiotic that inhibits Hsp90 activity
  • the growth of leukemia cell that express either wild type FLT3 or FLT3-ITD mutations was found to be inhibited by treatment with 17"AAG (Yao, et al, Clinical Cancer Research (2003), P:4483- 4493, the entire teachings of which are incorporated herein by reference).
  • c-Kit is a membrane type III receptor protein tyrosine kinase which binds Stem Cell Factor (SCF) to its extracellular domain.
  • SCF Stem Cell Factor
  • c-Kit has tyrosine kinase activity and is required for normal hematopoiesis.
  • mutations in c-kit can result in ligand-independent tyrosine kinase activity, autophosphorylation, and uncontrolled cell proliferation.
  • Aberrant expression and/or activation of c-Kit has been implicated in a variety of pathologic states.
  • evidence for a contribution of c-Kit to neoplastic pathology includes its association with leukemias and mast cell tumors, small cell lung cancer, testicular cancer, and some cancers of the gastrointestinal tract and central nervous system.
  • c-Kit has been implicated in playing a role in carcinogenesis of the female genital tract sarcomas of neuroectodermal origin, and Schwann cell neoplasia associated with neurofibromatosis.
  • c-Kit has been shown to be a client protein of Hsp90, and Hsp90 inhibitor 17 AAG, a benzoquinon ansamycin, has been shown to induce apoptosis in Kasumi-1 cells, an acute myeloid leukemia cell line that harbors a mutation in c-kit.
  • c-Met is a receptor tyrosine kinase that is encoded by the Met protooncogene and transduces the biological effects of hepatocyte growth factor (HGF), which is also referred to as scatter factor (SF).
  • HGF hepatocyte growth factor
  • SF scatter factor
  • c- Met and HGF are expressed in numerous tissues, although their expression is normally confined predominantly to cells of epithelial and mesenchymal origin, respectively.
  • c-Met and HGF are required for normal mammalian development and have been shown to be important in cell migration, cell proliferation and survival, morphogenic differentiation, and organization of 3 -dimensional tubular structures (e.g., renal tubular cells, gland formation, etc.).
  • the c-Met receptor has been shown to be expressed in a number of human cancers.
  • c-Met and its ligand, HGF have also been shown to be co-expressed at elevated levels in a variety of human cancers (particularly sarcomas).
  • c-Met signaling is most commonly regulated by tumor-stroma (tumor-host) interactions.
  • c-Met gene amplification, mutation, and rearrangement have been observed in a subset of human cancers. Families with germine mutations that activate c-Met kinase are prone to multiple kidney tumors as well as tumors in other tissues. Numerous studies have correlated the expression of c-Met and/or HGF/SF with the state of disease progression of different types of cancer (including lung, colon, breast, prostate, liver, pancreas, brain, kidney, ovarian, stomach, skin, and bone cancers).
  • BCR-ABL is an ocoprotein with tyrosine kinase activity and has been associated with chronic myelogenous leukemia (CML), with a subset of patients with acute lymphocytic leukemia (ALL) and with a subset of patients with acute myelogenous leukemia (AML).
  • CML chronic myelogenous leukemia
  • ALL acute lymphocytic leukemia
  • AML acute myelogenous leukemia
  • the BCR-ABL oncogene has been found in at least 90-95% of patients with CML, 20% of adults with ALL, 5% of children with ALL, and in about 2% of adults with AML.
  • the BCR-ABL oncoprotein is generated by the transloction of gene sequences from the c-ABL protein tyrosine kinase on chromosome 9 into the BCR sequences on chromosome 22, producing the Philadelphia chromosome.
  • the BCR-ABL gene has been shown to produce at least three alternative chimeric proteins, p230 Bcr-Abl, p210 Bcr-Abl, and pl90 Bcr-Abl which have unregulated tyrosine kinase activity.
  • the p210 Bcr-Abl fusion protein is most often associated with CML, while the pi 90 Bcr-Abl fusion protein is most often associated with ALL.
  • Bcr-Abl has also been associated with a variety of additional hematological malignancies including granulocytic hyperplasia, myelomonocytic leukemia, lymphomas and erythroid leukemia.
  • Bcr-Abl is effective in treating Bcr-Abl-positive leukemias.
  • agents such as As 2 O 3 which lower Bcr-Abl expression have been shown to be highly effective against Bcr-Abl leukemias.
  • Imatinib also known as STI571 and Gleevic
  • Imatinib induces differentiation and apoptosis and causes eradication of Bcr-Abl positive leukemia cells both in vivo and in vitro.
  • treatment with Imatinib typically will induce remission.
  • Bcr-Abl fusion proteins exist as complexes with Hsp90 and are rapidly degraded when the action of Hsp90 is inhibited. It has been shown that geldanamycin, a benzoquinone ansamycin antibiotic that disrupts the association of Bcr-Abl with Hsp90, results in proteasomal degradation of Bcr-Abl and induces apoptosis in Bcr-Abl leukemia cells.
  • Hsp90 has been shown by mutational analysis to be necessary for the survival of normal eukaryotic cells. However, Hsp90 is over expressed in many tumor types indicating that it may play a significant role in the survival of cancer cells and that cancer cells may be more sensitive to inhibition of Hsp90 than normal cells. For example, cancer cells typically have a large number of mutated and overexpressed oncoproteins that are dependent on Hsp90 for folding. In addition, because the environment of a tumor is typically hostile due to hypoxia, nutrient deprivation, acidosis, etc., tumor cells may be especially dependent on Hsp90 for survival.
  • Hsp90 a family of natural products that inhibit Hsp90, has shown evidence of therapeutic activity in clinical trials.
  • benzoquinone ansamycins suffer from a number of limitations. For example, they have low oral bioavailability, and their limited solubility makes them difficult to formula. In addition, they are metabolized by polymorphic cytochrome P450 CYP3A4 and are a substrate for P- glycoprotein export pump involved in the development of multidrug resistance. Therefore, a need exist for new therapeutics that improve the prognosis of cancer patients and that reduces or overcomes the limitations of currently used anti-cancer agents.
  • the present invention provides compounds which inhibit the activity of Hsp90 and are useful in the treatment of proliferative disorders, such as cancer.
  • the present invention also provides new uses for previously disclosed compounds.
  • the present invention also relates to compounds which inhibit the activity of
  • Hsp90 and are useful in the treatment of or prevention of infections.
  • the present invention also relates to the discovery that treatment of cells, such as peripheral blood mononuclear cells (PMBCs) that have been stimulated with an inflammatory stimulus, such as INF ⁇ /LPS or SAC, with an Hsp90 inhibitor reduces the expression of GR in the PMBCs and reduces the production of inflammatory cytokines.
  • PMBCs peripheral blood mononuclear cells
  • an Hsp90 inhibitor reduces the expression of GR in the PMBCs and reduces the production of inflammatory cytokines.
  • the present invention also relates to compounds which inhibit the activity of topoisomerase II.
  • the present invention provides compounds represented by structural formula (I):
  • Ring A is an aryl or a heteroaryl, wherein the aryl or the heteroaryl are optionally further substituted with one or more substituents in addition to R 3 ;
  • R 1 is -OH, -SH, -NR 7 H, -OR 26 , -SR 26 , -NHR 26 , -O(CH 2 ) m OH, -O(CH 2 ) m SH, -O(CH 2 ) m NR 7 H, -S(CH 2 ) m OH, -S(CH 2 ) m SH, -S(CH 2 ) m NR 7 H, -OC(O)NR 10 R 11 , -SC(O)NR 10 Rii, -NR 7 C(O)NR 10 RH, -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -NR 7 C(O)OR 7 , -OCH 2 C(O)R 7 , -SCH 2 C(O)R 7 , -NR 7 CH 2 C(O)R 7
  • R 3 is -OH, -SH, -NR 7 H, -NHR 26 , -O(CH 2 ) m OH, -O(CH 2 ) m SH, -O(CH 2 ) m NR 7 H, -S(CH 2 ) m OH, -S(CH 2 ) m SH, -S(CH 2 ) m NR 7 H, -OC(O)NR 10 R 1 1 , -SC(O)NR 10 R 11 , -NR 7 C(O)NR 10 R 1 1 , -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -NR 7 C(O)OR 7 , -OCH 2 C(O)R 7 , -SCH 2 C(O)R 7 , -NR 7 CH 2 C(O)R 7 , -OCH 2 C(
  • -SC(NR 8 )NR 10 Rii -NR 7 C(NR 8 )NR 10 Rii, -NR 7 C(NR 8 )NR 10 R 1 1 , -C(O)OH, -C(O)NHR 8 , -C(O)SH, -S(O)OH, -S(O) 2 OH, -S(O)NHR 8 , -S(O) 2 NHR 8 , -OP(O)(OR 7 ) 2 , or -SP(O)(OR 7 ) 2 .
  • -OR 26 and -SR 26 are additional values for R 3 ; ring B is further optionally substituted with one or more substituents in addition to -NR a R b ;
  • R a and R b for each occurrence, is independently -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl or heteroaryl, an optionally substituted aralkyl; or R a and R b , taken together with the nitrogen to which they are attached, form an optionally substituted heteroaryl or heterocyclyl;
  • R 7 and R 8 for each occurrence, is independently, -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl;
  • R 10 and R 11 for each occurrence, is independently -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; or R 10 and R 11 , taken together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl or an optionally substituted heteroaryl;
  • R 26 is a Cl -C6 alkyl; p, for each occurrence, is independently, O, 1 or 2; and m, for each occurrence, is independently, 1 , 2, 3 or 4.
  • the present invention provides compounds represented by a structural formula selected from (II) and (III):
  • ring B is further optionally substituted with one or more substituents in addition to -NR a R b ;
  • Ri is -OH, -SH, -NR 7 H, -OR 26 , -SR 26 , -NHR 26 , -O(CH 2 ) m OH,
  • R 3 is -OH, -SH, -NR 7 H, -OR 26 , -SR 26 , -NHR 26 , -0(CH 2 ) m 0H, -O(CH 2 ) m SH, -O(CH 2 ) m NR 7 H, -S(CH 2 ) m OH, -S(CH 2 ) m SH, -S(CH 2 ) m NR 7 H, -OC(O)NR 10 Rn, -SC(O)NR 10 R H , -NR 7 C(O)NR I0 R 1 1 , -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -NR 7 C(O)OR 7 , -OCH 2 C(O)R 7 , -SCH 2 C(O)R 7 , -NR 7 CH 2 C(O
  • R 7 and R 8 for each occurrence, is independently, -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl;
  • Ri 0 and R 11 for each occurrence, is independently -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; or
  • R 22 for each occurrence, is independently -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl, a haloalkyl, -C(O)R 7 , -C(O)OR 7 , -OC(O)R 7 , -C(O)NRi 0 Rn, -NR 8 C(O)R 7 , -S(O) P R 7 , -S(O) p OR 7 , or -S(O) p NR 10 Ri,; R 23 and R 24 , for each occurrence, is independently -H, an optionally substituted alky, an optionally substituted
  • R 26 is a Cl-C6 alkyl;
  • R a and R b for each occurrence, is independently -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl or heteroaryl, an optionally substituted aralkyl; or R a and R b , taken together with the nitrogen to which they are attached, form an optionally substituted heteroaryl or heterocyclyl;
  • Xi 4 is O, S, or NR 7 .
  • X H is O; p, for each occurrence, is independently, O, 1 or 2; and m, for each occurrence, is independently, 1, 2, 3, or 4.
  • the present invention is a method of inhibiting Hsp90 in a mammal in need of such treatment.
  • the method comprises administering to the mammal an effective amount of an Hsp90 inhibitor disclosed herein.
  • Yet another embodiment of the present invention is a method of inhibiting Hsp90 in a cell.
  • the method comprises administering to the cell an effective amount of an Hsp90 inhibitor disclosed herein.
  • Yet another embodiment of the present invention is a method of treating a proliferative disorder in a mammal comprising administering an effective amount of an Hsp90 inhibitor disclosed herein.
  • Another embodiment of the present invention is a method of treating cancer in a mammal.
  • the method comprises administering to the mammal an effective amount of an Hsp90 inhibitor disclosed herein.
  • Yet another embodiment of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising an Hsp90 inhibitor disclosed herein and a pharmaceutically acceptable carrier.
  • the pharmaceutical compositions can be used in therapy, e.g., to inhibit Hsp90 activity in a mammal in need of such inhibition, to treat a mammal with a proliferative disorder, or to treat a mammal with cancer.
  • Yet another embodiment of the present invention is the use of an Hsp90 inhibitor disclosed herein for the manufacture of a medicament for inhibiting Hsp90 in a mammal in need of such inhibition or for treating a mammal with cancer.
  • Hsp90 is necessary for the survival of normal eukaryotic cells.
  • Hsp90 is over expressed in many tumor types indicating that it may play a significant role in the survival of cancer cells and that cancer cells may be more sensitive to inhibition of Hsp90 than normal cells.
  • the compounds shown in Table 1 or 2 or compounds of any formula herein, or tautomers, pharmaceutically acceptable salts, solvates, clathrates, hydrates, polymorphs or prodrugs thereof, are useful treating proliferative disorders such as cancer.
  • chemotherapeutic agents initially cause tumor regression, most agents that are currently used to treat cancer target only one pathway to tumor progression. Therefore, in many instances, after treatment with one or more chemotherapeutic agents, a tumor develops multidrug resistance and no longer responses positively to treatment.
  • One of the advantages of inhibiting Hsp90 activity is that several of its client proteins, which are mostly protein kinases or transcription factors involved in signal transduction, have been shown to be involved in the progression of cancer. Thus, inhibition of Hsp90 provides a method of short circuiting several pathways for tumor progression simultaneously.
  • treatment of tumors with an Hsp90 inhibitor of the invention is more likely to result in regression or elimination of the tumor, and less likely to result in the development of more aggressive multidrug resistant tumors than other currently available therapies.
  • Figure 1 is a graph showing an FACSCalibur flow cytometer analysis of the c-kit positive population of Kasumi-1 cells treated with Hsp90 inhibitors of the invention or 17AAG (as a positive control). The results indicate that the Hsp90 inhibitors of the invention induce c-kit degradation at a lower concentration than 17 AAG, an Hsp90 inhibitor that is currently in phase II clinical trials.
  • Figure 2 is a Western blot analysis of the c-kit from Kasumi-1 cells treated with Hsp90 inhibitors of the invention or 17AAG (as a positive control).
  • Figure 3 is a Western blot analysis of the c-met from NCI-Hl 193 cells treated with Hsp90 inhibitors of the invention or 17AAG (as a positive control).
  • the present invention provides compounds disclosed herein and uses of said compounds to inhibit Hsp90 activity and for the treatment of a proliferative disorder, such as cancer.
  • the present invention encompasses the use of compounds of the invention to slow or stop the growth of cancerous cells or to reduce or eliminate cancerous cells in a subject, preferably the subject is a mammal.
  • the compounds of the invention can be used in combination with other chemotherapeutic agents and may help to prevent or reduce the development of multidrug resistant cancerous cells in a mammal.
  • the compounds of the invention may allow a reduced efficacious amount of a second chemotherapeutic agent given to a mammal, because compounds of the invention should inhibit the development of multidrug resistant cancerous cells.
  • alkyl means a saturated straight chain or branched non-cyclic hydrocarbon having from 1 to 10 carbon atoms.
  • Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n- heptyl, n-octyl, n-nonyl and n-decyl; while saturated branched alkyls include isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, 2-methylbutyl, 3-methylbutyl, 2- methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4- methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, 2,3-dimethylpentyl, 2,4- dimethylpentyl
  • (Ci-C 6 )alkyl means a saturated straight chain or branched non-cyclic hydrocarbon having from 1 to 6 carbon atoms.
  • Representative (Ci-C 6 )alkyl groups are those shown above having from 1 to 6 carbon atoms.
  • Alkyl groups included in compounds of this invention may be optionally substituted with one or more substituents.
  • alkenyl means a saturated straight chain or branched non-cyclic hydrocarbon having from 2 to 10 carbon atoms and having at least one carbon-carbon double bond.
  • Representative straight chain and branched (C 2 -Cio)alkenyls include vinyl, allyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl- 1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, 1- hexenyl, 2-hexenyl, 3-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 1-octenyl, 2- octenyl, 3-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 2-decenyl, 3- decenyl and the like.
  • alkynyl means a saturated straight chain or branched non-cyclic hydrocarbon having from 2 to 10 carbon atoms and having at least one carbon-carbon triple bond.
  • Representative straight chain and branched alkynyls include acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl- 1-butynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 5-hexynyl, 1-heptynyl, 2- heptynyl, 6-heptynyl, 1-octynyl, 2-octynyl, 7-octynyl, 1-nonynyl, 2-nonynyl, 8- nonynyl, 1-decynyl, 2-decynyl, 9-decynyl, and the
  • cycloalkyl means a saturated, mono- or polycyclic alkyl radical having from 3 to 20 carbon atoms.
  • Representative cycloalkyls include cyclopropyl, 1-methylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, -cyclodecyl, octahydro-pentalenyl, and the like.
  • Cycloalkyl groups may be optionally substituted with one or more substituents.
  • cycloalkenyl means a mono- or poly- cyclic non- aromatic alkyl radical having at least one carbon-carbon double bond in the cyclic system and from 3 to 20 carbon atoms.
  • Representative cycloalkenyls include cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl.cycloheptenyl, cycloheptadienyl, cycloheptatrienyl, cyclooctenyl, cyclooctadienyl, cyclooctatrienyl, cyclooctatetraenyl, cyclononenyl, cyclononadienyl, cyclodecenyl, cyclodecadienyl, 1,2,3, 4,5, 8-hexahydronaphthalenyl and the like. Cycloalkenyl groups may be optionally substituted with one or more substituent
  • haloalkyl means an alkyl group, in which one or more (including all) the hydrogen radicals are replaced by a halo group, wherein each halo group is independently selected from -F, -Cl, -Br, and -I.
  • halomethyl means a methyl in which one to three hydrogen radical(s) have been replaced by a halo group.
  • Representative haloalkyl groups include trifluoromethyl, bromomethyl, 1 ,2-dichloroethyl, 4-iodobutyl, 2-fluoropentyl, and the like.
  • an "alkoxy” is an alkyl group which is attached to another moiety via an oxygen linker.
  • haloalkoxy is a haloalkyl group which is attached to another moiety via an oxygen linker.
  • an "aromatic ring” or “aryl” means a hydrocarbon monocyclic or polycyclic radical in which at least one ring is aromatic.
  • suitable aryl groups include, but are not limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl.
  • Aryl groups may be optionally substituted with one or more substituents.
  • the aryl group is a monocyclic ring, wherein the ring comprises 6 carbon atoms, referred to herein as "(C 6 )aryl.”
  • aralkyl means an aryl group that is attached to another group by a (Ci-C 6 )alkylene group.
  • Representative aralkyl groups include benzyl, 2-phenyl-ethyl, naphth-3-yl-methyl and the like.
  • Aralkyl groups may be optionally substituted with one or more substituents.
  • alkylene refers to an alkyl group that has two points of attachment.
  • (C]-C 6 )alkylene refers to an alkylene group that has from one to six carbon atoms.
  • Straight chain (Ci-C 6 )alkylene groups are preferred.
  • Non-limiting examples of alkylene groups include methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), n-propylene (-CH 2 CH 2 CH 2 -), isopropylene (-CH 2 CH(CH 3 )-), and the like.
  • Alkylene groups may be optionally substituted with one or more substituents.
  • heterocyclyl means a monocyclic (typically having 3- to 10-members) or a polycyclic (typically having 7- to 20-members) heterocyclic ring system which is either a saturated ring or a unsaturated non- aromatic ring.
  • a 3- to 10-membered heterocycle can contain up to 5 heteroatoms; and a 7- to 20-membered heterocycle can contain up to 7 heteroatoms.
  • a heterocycle has at least one carbon atom ring member.
  • Each heteroatom is independently selected from nitrogen, which can be oxidized (e.g., N(O)) or quaternized; oxygen; and sulfur, including sulfoxide and sulfone.
  • the heterocycle may be attached via any heteroatom or carbon atom.
  • Representative heterocycles include morpholinyl, thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyrindinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.
  • a heteroatom may be substituted with a protecting group known to those of ordinary skill in the art, for example, the hydrogen on a nitrogen may be substituted with a tert-butoxycarbonyl group.
  • the heterocyclyl may be optionally substituted with one or more substituents. Only stable isomers of such substituted heterocyclic groups are contemplated in this definition.
  • heteroaryl means a monocyclic or polycyclic heteroaromatic ring comprising carbon atom ring members and one or more heteroatom ring members.
  • Each heteroatom is independently selected from nitrogen, which can be oxidized (e.g., N(O)) or quaternized; oxygen; and sulfur, including sulfoxide and sulfone.
  • heteroaryl groups include pyridyl, 1 -oxo-pyridyl, furanyl, benzo[l,3]dioxolyl, benzo[l,4]dioxinyl, thienyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, a isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, a triazinyl, triazolyl, thiadiazolyl, isoquinolinyl, indazolyl, benzoxazolyl, benzofuryl, indolizinyl, imidazopyridyl, tetrazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, indolyl, tetrahydro
  • the heteroaromatic ring is selected from 5-8 membered monocyclic heteroaryl rings.
  • the point of attachment of a heteroaromatic or heteroaryl ring may be at either a carbon atom or a heteroatom of the heteroaromatic or heteroaryl rings.
  • Heteroaryl groups may be optionally substituted with one or more substituents.
  • the term "(C 5 )heteroaryl” means an aromatic heterocyclic ring of 5 members, wherein at least one carbon atom of the ring is replaced with a heteroatom such as, for example, oxygen, sulfur or nitrogen.
  • Representative (Cs)heteroaryls include furanyl, thienyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyrazinyl, triazolyl, thiadiazolyl, and the like.
  • the term "(C 6 )heteroaryl” means an aromatic heterocyclic ring of 6 members, wherein at least one carbon atom of the ring is replaced with a heteroatom such as, for example, oxygen, nitrogen or sulfur. Representative
  • (C 6 )heteroaryls include pyridyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl and the like.
  • heteroarylkyl means a heteroaryl group that is attached to another group by a (Ci-C 6 )alkylene.
  • Representative heteroaralkyls include 2-(pyridin-4-yl)-propyl, 2-(thien-3-yl)-ethyl, imidazol-4-yl-methyl and the like.
  • Heteroaralkyl groups may be optionally substituted with one or more substituents.
  • halogen or “halo” means -F, -Cl, -Br or -I.
  • heteroalkyl means a linear straight or branched chain alkyl group, wherein one or more of the internal carbon atoms in the chain is replaced by a heteroatom, such as, O, N or S, e.g., -[CH 2 ] X -O-[CH 2 J y [CH 3 ] wherein x is a positive integer and y is 0 or a positive integer, and wherein replacement of the carbon atom does not result in a unstable compound.
  • Suitable substituents for an alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, aralkyl, heteroaryl, and heteroaralkyl groups include are those substituents which form a stable compound of the invention without significantly adversely affecting the reactivity or biological activity of the compound of the invention.
  • substituents for an alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, aralkyl, heteroaryl, and heteroarylalkyl include an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, an optionally substituted haloalkyl, an optionally substituted heteroalkyl, optionally substituted alkoxy, -C(O)NR 28 R 29 , -C(S)NR 28 R 29 , -C(NR 32 )NR 28 R 29 , -NR 33 C(O)R 31 ,
  • R 33 and R 3 for each occurrence is independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl (preferably the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, and heteraralkyl are unsubstituted); and
  • R 32 for each occurrence is independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, -C(O)R 33 , -C(O)NR 28 R 29 , -S(O)pR 33 , or -S(O) P NR 28 R 29 (preferably the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl and heteraralkyl are unsubstituted); p is 0, 1 or 2; and h is 0, 1 or 2.
  • heterocyclyl, heteroaryl, or heteroaralkyl group When a heterocyclyl, heteroaryl, or heteroaralkyl group contains a nitrogen atom, it may be substituted or unsubstituted. When a nitrogen atom in the aromatic ring of a heteroaryl group has a substituent the nitrogen may be a quaternary nitrogen.
  • the terms "subject”, “patient” and “mammal” are used interchangeably.
  • subject and “patient” refer to an animal (e.g., a bird such as a chicken, quail or turkey, or a mammal), preferably a mammal including a non-primate (e.g., a cow, pig, horse, sheep, rabbit, guinea pig, rat, cat, dog, and mouse) and a primate (e.g., a monkey, chimpanzee and a human), and more preferably a human.
  • the subject is a non-human animal such as a farm animal (e.g., a horse, cow, pig or sheep), or a pet (e.g., a dog, cat, guinea pig or rabbit).
  • the subject is a human.
  • lower refers to a group having up to four atoms.
  • a “lower alkyl” refers to an alkyl radical having from 1 to 4 carbon atoms
  • “lower alkoxy” refers to "-O-(Ci-C 4 )alkyl
  • a “lower alkenyl” or “lower alkynyl” refers to an alkenyl or alkynyl radical having from 2 to 4 carbon atoms, respectively.
  • the compounds of the invention containing reactive functional groups also include protected derivatives thereof.
  • "Protected derivatives” are those compounds in which a reactive site or sites are blocked with one ore more protecting groups.
  • suitable protecting groups for hydroxyl groups include benzyl, methoxymethyl, allyl, trimethylsilyl, tert-butyldimethylsilyl, acetate, and the like.
  • suitable amine protecting groups include benzyloxycarbonyl, tert-butoxycarbonyl, tert-butyl, benzyl and fiuorenylmethyloxy- carbonyl (Fmoc).
  • thiol protecting groups examples include benzyl, tert- butyl, acetyl, methoxymethyl and the like.
  • Other suitable protecting groups are well known to those of ordinary skill in the art and include those found in T. W. Greene, Protecting Groups in Organic Synthesis, John Wiley & Sons, Inc. 1981.
  • compound(s) of this invention refers to a compound of formula (I)- (XXXVI), or Table 1 or 2, or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, polymorph or prodrug thereof, and also include protected derivatives thereof.
  • the compounds of the invention may contain one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), enantiomers, or diastereomers.
  • stereoisomers such as double-bond isomers (i.e., geometric isomers), enantiomers, or diastereomers.
  • the chemical structures depicted herein, including the compounds of this invention encompass all of the corresponding compounds' enantiomers, diastereomers and geometric isomers, that is, both the stereochemically pure form (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and isomeric mixtures (e.g., enantiomeric, diastereomeric and geometric isomeric mixtures).
  • one enantiomer, diastereomer or geometric isomer will possess superior activity or an improved toxicity or kinetic profile compared to other isomers. In those cases, such enantiomers, diastereomers and geometric isomers of compounds of this invention are preferred.
  • polymorph means solid crystalline forms of a compound of the present invention or complex thereof. Different polymorphs of the same compound can exhibit different physical, chemical and/or spectroscopic properties. Different physical properties include, but are not limited to stability (e.g., to heat or light), compressibility and density (important in formulation and product manufacturing), and dissolution rates (which can affect bioavailability). Differences in stability can result from changes in chemical reactivity (e.g.
  • differential oxidation such that a dosage form discolors more rapidly when comprised of one polymorph than when comprised of another polymorph
  • mechanical characteristics e.g., tablets crumble on storage as a kinetically favored polymorph converts to thermodynamically more stable polymorph
  • both e.g. , tablets of one polymorph are more susceptible to breakdown at high humidity.
  • Different physical properties of polymorphs can affect their processing. For example, one polymorph might be more likely to form solvates or might be more difficult to filter or wash free of impurities than another due to, for example, the shape or size distribution of particles of it.
  • hydrate means a compound of the present invention or a salt thereof, that further includes a stoichiometric or non- stoichiometric amount of water bound by non-covalent intermolecular forces.
  • clathrate means a compound of the present invention or a salt thereof in the form of a crystal lattice that contains spaces (e.g. , channels) that have a guest molecule (e.g., a solvent or water) trapped within.
  • prodrug means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide a compound of this invention. Prodrugs may become active upon such reaction under biological conditions, or they may have activity in their unreacted forms.
  • prodrugs contemplated in this invention include, but are not limited to, analogs or derivatives of compounds of formula (I) - (XXXVI) or Table 1 or 2 that comprise biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues.
  • Other examples of prodrugs include derivatives of compounds of formula (I) - (XXXVI) or Table 1 or 2 that comprise -NO, -NO 2 , -ONO, or - ONO 2 moieties.
  • Prodrugs can typically be prepared using well-known methods, such as those described by 1 BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY (1995) 172-178, 949-982 (Manfred E. Wolff ed., 5 th ed).
  • biohydrolyzable amide means an amide, ester, carbamate, carbonate, ureide, or phosphate analogue, respectively, that either: 1) does not destroy the biological activity of the compound and confers upon that compound advantageous properties in vivo, such as improved water solubility, improved circulating half-life in the blood (e.g., because of reduced metabolism of the prodrug), improved uptake, improved duration of action, or improved onset of action; or 2) is itself biologically inactive but is converted in vivo to a biologically active compound.
  • biohydrolyzable amides include, but are not limited to, lower alkyl amides, ⁇ -amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides.
  • biohydrolyzable esters include, but are not limited to, lower alkyl esters, alkoxyacyloxy esters, alkyl acylamino alkyl esters, and choline esters.
  • biohydrolyzable carbamates include, but are not limited to, lower alkylamines, substituted ethyl enediamines, aminoacids, hydroxyalkylamines, heterocyclic and heteroaromatic amines, and polyether amines.
  • Hsp90 includes each member of the family of heat shock proteins having a mass of about 90-kiloDaltons.
  • the highly conserved Hsp90 family includes cytosolic Hsp90 ⁇ and Hsp90 ⁇ isoforms, as well as GRP94, which is found in the endoplasmic reticulum, and HSP75/TRAP1, which is found in the mitochondrial matrix.
  • c-kit or "c-kit kinase” refers to a membrane receptor protein tyrosine kinase which is preferably activated upon binding Stem Cell Factor (SCF) to its extracellular domain (Yarden et al., 1987; Qiu et al, 1988).
  • SCF Stem Cell Factor
  • the full length amino acid sequence of a c-kit kinase preferably is as set forth in Yarden, et al, 1987, EMBO J, 77:3341-3351; and Qiu, et al., ⁇ 988, EMBO J., 7:1003-1011, which are incorporated by reference herein in their entirety, including any drawings.
  • c-kit or “c-kit kinase” and include those that fall into two classes: (1) having a single amino acid substitution at codon 816 of the human c-kit kinase, or its equivalent position in other species (Ma et al, 1999, J. Invest Dermatol, 772:165-170), and (2) those which have mutations involving the putative juxtamembrane z-helix of the protein (Ma, et al, 1999, J. Biol. Chem., 274:13399-13402). Both of these publications are incorporated by reference herein in their entirety, including any drawings.
  • Bcr-Abl is a fusion protein that results from the translocation of gene sequences from c-ABL protein tyrosine kinase on chromosome 9 into BCR sequences on chromosome 22 producing the Philadelphia chromosome.
  • a schematic representation of human Bcr, AbI, and Bcr-Abl can be seen in Figure 1 of U.S. patent application serial number 10/193,651, filed on July 9, 2002, the entire teachings of which are incorporated herein by reference.
  • Bcr-Abl fusion proteins can vary in size from 185-230 kDa but they must contain at least the OLI domain from Bcr and the TK domain from AbI for transforming activity.
  • FLT3 kinase is a tyrosine kinase receptor involved in the regulation and stimulation of cellular proliferation (see Gilliland et al, Blood (2002), 700:1532-42, the entire teachings of which are incorporated herein by reference).
  • the FLT3 kinase has five immunoglobulin-like domains in its extracellular region as well as an insert region of 75-100 amino acids in the middle of its cytoplasmic domain.
  • FLT3 kinase is activated upon the binding of the FLT3 ligand, which causes receptor dimerization. Dimerization of the FLT3 kinase by FLT3 ligand activates the intracellular kinase activity as well as a cascade of downstream substrates including Stat5, Ras, phosphatidylinositol-3-kinase (PI3K), PLC ⁇ , Erk2, Akt, MAPK, SHC, SHP2, and SHIP (see Rosnet et al, Acta Haematol.
  • Normal cells that express FLT3 kinase include immature hematopoietic cells, typically CD34+ cells, placenta, gonads, and brain (see Rosnet, et al, Blood (1993), 52:11 10-19; Small et al, Proc. Natl. Acad. ScL U.S.A. (1994), 97:459-63; and Rosnet et al, Leukemia (1996), 70:238-48, the entire teachings of each of these references are incorporated herein by reference).
  • efficient stimulation of proliferation via FLT3 kinase typically requires other hematopoietic growth factors or interleukins.
  • FLT3 kinase also plays a critical role in immune function through its regulation of dendritic cell proliferation and dilferentiation (see McKenna et al, Blood (2000), 95:3489-97, the entire teachings of which are incorporated herein by reference).
  • FLT3 kinase Numerous hematologic malignancies express FLT3 kinase, the most prominent of which is AML (see Yokota et al, Leukemia (1997), 77: 1605-09, the entire teachings of which are incorporated herein by reference).
  • FLT3 expressing malignancies include B-precursor cell acute lymphoblastic leukemias, myelodysplastic leukemias, T-cell acute lymphoblastic leukemias, and chronic myelogenous leukemias (see Rasko et al., Leukemia (1995), 9:2058-66, the entire teachings of which are incorporated herein by reference).
  • FLT3 kinase mutations associated with hematologic malignancies are activating mutations.
  • the FLT3 kinase is constitutively activated without the need for binding and dimerization by FLT3 ligand, and therefore stimulates the cell to grow continuously.
  • Two types of activating mutations have been identified: internal tandem duplications (ITDs) and point mutation in the activating loop of the kinase domain.
  • ITDs internal tandem duplications
  • FLT3 kinase refers to both wild type FLT3 kinase and mutant FLT3 kinases, such as FLT3 kinases that have activating mutations.
  • Inappropriate FLT3 activity includes, but is not limited to, enhanced FLT3 activity resulting from increased or de novo expression of FLT3 in cells, increased FLT3 expression or activity, and FLT3 mutations resulting in constitutive activation.
  • the existence of inappropriate or abnormal FLT3 ligand and FLT3 levels or activity can be determined using well known methods in the art. For example, abnormally high FLT3 levels can be determined using commercially available ELISA kits. FLT3 levels can be determined using flow cytometric analysis, immunohistochemical analysis, and in situ hybridization techniques.
  • EGFR epidermal growth factor receptor
  • EGFR epidermal growth factor receptor
  • peptide peptide
  • polypeptide having EGFR or EGFR family (e.g., HERl, HER2, HER3, and/or HER4) activity (such as encoded by EGFR Genbank Accession Nos. shown in Table I of U.S. Patent Application Serial No. 10/923,354, filed on August 20, 2004 , the entire teachings of which are incorporated herein by reference), or any other EGFR transcript derived from a EGFR gene and/or generated by EGFR translocation.
  • EGFR epidermal growth factor receptor
  • EGFR is also meant to include other EGFR protein, peptide, or polypeptide derived from EGFR isoforms (e.g., HERl, HER2, HER3, and/or HER4), mutant EGFR genes, splice variants of EGFR genes, and EGFR gene polymorphisms.
  • a "proliferative disorder” or a “hyperproliferative disorder,” and other equivalent terms, means a disease or medical condition involving pathological growth of cells.
  • Proliferative disorders include cancer, smooth muscle cell proliferation, systemic sclerosis, cirrhosis of the liver, adult respiratory distress syndrome, idiopathic cardiomyopathy, lupus erythematosus, retinopathy, e.g., diabetic retinopathy or other retinopathies, cardiac hyperplasia, reproductive system associated disorders such as benign prostatic hyperplasia and ovarian cysts, pulmonary fibrosis, endometriosis, fibromatosis, harmatomas, lymphangiomatosis, sarcoidosis, desmoid tumors,
  • Smooth muscle cell proliferation includes hyperproliferation of cells in the vasculature, for example, intimal smooth muscle cell hyperplasia, restenosis and vascular occlusion, particularly stenosis following biologically- or mechanically- mediated vascular injury, e.g., vascular injury associated with angioplasty.
  • intimal smooth muscle cell hyperplasia can include hyperplasia in smooth muscle other than the vasculature, e.g., bile duct blockage, bronchial airways of the lung in patients with asthma, in the kidneys of patients with renal interstitial fibrosis, and the like.
  • Non-cancerous proliferative disorders also include hyperproliferation of cells in the skin such as psoriasis and its varied clinical forms, Reiter's syndrome, pityriasis rubra pilaris, and hyperproliferative variants of disorders of keratinization (e.g., actinic keratosis, senile keratosis), scleroderma, and the like.
  • the proliferative disorder is cancer.
  • Cancers that can be treated or prevented by the methods of the present invention include, but are not limited to human sarcomas and carcinomas, e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medu
  • leukemias include acute and/or chronic leukemias, e.g., lymphocytic leukemia (e.g., as exemplified by the p388 (murine) cell line), large granular lymphocytic leukemia, and lymphoblastic leukemia; T-cell leukemias, e.g., T-cell leukemia (e.g., as exemplified by the CEM, Jurkat, and HSB-2 (acute), YAC- 1 (murine) cell lines), T-lymphocytic leukemia, and T-lymphoblastic leukemia; B cell leukemia (e.g., as exemplified by the SB (acute) cell line) , and B-lymphocytic leukemia; mixed cell leukemias, e.g., B and T cell leukemia and B and T lymphocytic leukemia; myeloid leukemias, e.g., granuloc
  • the disclosed method is believed to be particularly effective in treating subject with non-solid tumors such as multiple myeloma.
  • the disclosed method is believed to be particularly effective against T-leukemia (e.g., as exemplified by Jurkat and CEM cell lines); B-leukemia (e.g., as exemplified by the SB cell line); promyelocytes (e.g., as exemplified by the HL-60 cell line); uterine sarcoma (e.g., as exemplified by the MES-SA cell line); monocytic leukemia (e.g., as exemplified by the THP-I (acute) cell line); and lymphoma (e.g., as exemplified by the U937 cell line).
  • T-leukemia e.g., as exemplified by Jurkat and CEM cell lines
  • B-leukemia e.g., as exemplified by the SB cell line
  • the disclosed method is believed to be particularly effective in treating subject with non-Hodgkin's lymphoma (NHL).
  • Lymphomas are generally classified as either Hodgkin's disease (HD) or non-Hodgkin's lymphomas (NHL).
  • NHL differs from HD by the absence of Reed-Sternberg cells. The course of NHL is less predictable than HD and is more likely to spread to areas beyond the lymph nodes. NHL can be further divided into B-cell NHL and T-cell NHL each of which can be further categorized into a variety of different subtypes.
  • B-cell NHL includes Burkitt's lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, nodal marginal zone B-cell lymphoma, plasma cell neoplasms, small lymphocytic lymphoma/chronic lymphocytic leukemia, mantle cell lymphoma, extranodal marginal zone B-cell lymphoma, and lymphoplamacytic lymphoma/Waldenstrom macroglobulinemia.
  • T-cell NHL include anaplastic large- cell lymphoma, precursor-T-cell lymphoblastic leukemia/lymphoma, unspecified peripheral T-cell lymphoma, acute lymphoblastic leukemia/lymphoma, angioimmunoblastic T-cell lymphoma, and mycosis fungoides.
  • the compounds of the invention are useful for treating NHLs, including B-cell and T- cell NHLs, since Hsp90 is upregulated in many NHLs.
  • NHLs including B-cell and T- cell NHLs
  • Hsp90 was found to be moderately to strongly over expressed in all cases of Burkitt's lymphoma (5/5, 100%), and in a subset of follicular lymphoma (17/28, 61%), diffuse large B-cell lymphoma (27/46, 59%), nodal marginal zone B-cell lymphoma (6/16, 38%), plasma cell neoplasms (14/39, 36%), small lymphocytic lymphoma/chronic lymphocytic leukemia (3/9, 33%), mantle cell lymphoma (12/38, 32%), and lymphoplamacytic lymphoma/Waldenstrom macroglobulinemia (3/10, 30%).
  • Hsp90 was found to be moderately to strongly over expressed in a subset of anaplastic large-cell lymphoma (14/24, 58%), precursor-T-cell lymphoblastic leukemia/lymphoma (20/65, 31%), unspecified peripheral T-cell lymphoma (8/43, 23%), and angioimmunoblastic T-cell lymphoma (2/17, 12%).
  • anaplastic large-cell lymphoma 14/24, 58%
  • precursor-T-cell lymphoblastic leukemia/lymphoma (20/65, 31%)
  • unspecified peripheral T-cell lymphoma 8/43, 23%)
  • angioimmunoblastic T-cell lymphoma 2/17, 12%.
  • Some of the disclosed methods can be particularly effective at treating subjects whose cancer has become "multi-drug resistant".
  • a cancer which initially responded to an anti-cancer drug becomes resistant to the anti-cancer drug when the anti-cancer drug is no longer effective in treating the subject with the cancer.
  • many tumors will initially respond to treatment with an anti-cancer drug by decreasing in size or even going into remission, only to develop resistance to the drug.
  • Drug resistant tumors are characterized by a resumption of their growth and/or reappearance after having seemingly gone into remission, despite the administration of increased dosages of the anti-cancer drug.
  • Cancers that have developed resistance to two or more anti-cancer drugs are said to be "multi-drug resistant". For example, it is common for cancers to become resistant to three or more anti-cancer agents, often five or more anti-cancer agents and at times ten or more anti-cancer agents.
  • compounds of the invention are vascular targeting agents.
  • compounds of the invention are effective for blocking, occluding, or otherwise disrupting blood flow in "neovasculature.”
  • the invention provides a novel treatment for diseases involving the growth of new blood vessels ("neovasculature"), including, but not limited to: cancer; infectious diseases; autoimmune disorders; benign tumors, e.g.
  • hemangiomas acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; artheroscleric plaques; ocular angiogenic diseases, e.g., diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, persistent hyperplastic vitreous syndrome, choroidal neovascularization, uvietis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; warts; allergic dermatitis; blistering disease; Karposi sarcoma; delayed wound healing; endometriosis; uterine bleeding; ovarian cysts; ovarian hyperstimulation; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion
  • angiogenesis refers to a fundamental process of generating new blood vessels in tissues or organs.
  • Angiogenesis is involved with or associated with many diseases or conditions, including, but not limited to: cancer; ocular neovascular disease; age-related macular degeneration; diabetic retinopathy, retinopathy of prematurity; corneal graft rejection; neovascular glaucoma; retrolental fibroplasias; epidemic keratoconjunctivitis; Vitamin A deficiency; contact lens overwear; atopic keratitis; superior limbic keratitis; pterygium keratitis sicca; sjogrens; acne rosacea; warts; eczema; phylectenulosis; syphilis; Mycobacteria infections; lipid degeneration; chemical burns; bacterial ulcers; fungal ulcers; Herpes simplex infections; Herpes zoster infections; protoz
  • infection is used herein in its broadest sense and refers to any infection e.g. a viral infection or one caused by a microorganism: bacterial infection, fungal infection, or parasitic infection (e.g. protozoal, amoebic, or helminth).
  • Bacillus infections include, but are not limited to, infections caused by Gram Positive Bacteria including Bacillus cereus, Bacillus anthracis, Clostridium botulinum, Clostridium difficile, Clostridium tetani, Clostridium perfringens, Corynebacteria diphtheriae, Enterococcus (Streptococcus D), Listeria monocytogenes, Pneumoccoccal infections (Streptococcus pneumoniae), Staphylococcal infections and Streptococcal infections; Gram Negative Bacteria including Bacteroides, Bordetella pertussis, Brucella, Campylobacter infections, enterohaemorrhagic Escherichia coli (EHEC/E.
  • Gram Positive Bacteria including Bacillus cereus, Bacillus anthracis, Clostridium botulinum, Clostridium difficile, Clostridium tetani, Clostridium perfringens, Coryne
  • EIEC enteroinvasive Escherichia coli
  • ETEC enterotoxigenic Escherichia coli
  • Haemophilus influenzae Helicobacter pylori
  • Klebsiella pneumoniae Legionella spp.
  • Moraxella catarrhalis Neisseria gonnorrhoeae
  • Neisseria meningitidis Proteus spp.
  • Pseudomonas aeruginosa Salmonella spp., Shigella spp., Vibrio cholera and
  • Yersinia acid fast bacteria including Mycobacterium tuberculosis, Mycobacterium avium-intracellulare, Myobacterium johnei, Mycobacterium leprae, atypical bacteria, Chlamydia, Mycoplasma, Rickettsia, Spirochetes, Treponema pallidum, Borrelia recurrentis, Borrelia burgdorf ⁇ and Leptospira icterohemorrhagiae; or other miscellaneous bacteria, including Actinomyces and Nocardia.
  • fungus refers to a distinct group of eukaryotic, spore- forming organisms with absorptive nutrition and lacking chlorophyll. It includes mushrooms, molds, and yeasts.
  • "Fungal infections” include, but are not limited to, infections caused by Alternaria alternata, Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger, Aspergillus versicolor, Blastomyces dermatiditis, Candida albicans, Candida dubliensis, Candida krusei, Candida parapsilosis, Candida tropicalis, Candida glabrata, Coccidioides immitis, Cryptococcus neoformans, Epidermophyton floccosum, Histoplasma capsulatum, Malassezia furfur, Microsporum canis, Mucor spp., Paracoccidioides brasiliensis, Penicillium marneffe
  • “Parasitic infections” include, but are not limited to, infections caused by Leishmania, Toxoplasma, Plasmodia, Theileria, Acanthamoeba, Anaplasma, Giardia, Trichomonas, Trypanosoma, Coccidia, and Babesia.
  • parasitic infections include those caused by Trypanosoma cruzi, Eimeria tenella, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Cryptosporidium parvum, Naegleria fowleri, Entamoeba histolytica, Balamuthia mandrillaris, Entameoba histolytica, Schistostoma mansoni,
  • the term "viral infection” refers to any stage of a viral infection, including incubation phase, latent or dormant phase, acute phase, and development and maintenance of immunity towards a virus. Consequently, the term “treatment” is meant to include aspects of generating or restoring immunity of the patient's immune system, as well as aspects of suppressing or inhibiting viral replication.
  • Viral infections include, but are not limited to those caused by Adenovirus, Lassa fever virus (Arenavirus), Astrovirus, Hantavirus, Rift Valley Fever virus (Phlebovirus), Calicivirus, Ebola virus, Marburg Virus, Japanese encephalitis virus, Dengue virus, Yellow fever virus, Hepatitis C virus, Hepatitis G virus, Hepatitis B virus, Hepatitis D virus, Herpes simplex virus 1 , Herpes simplex virus 2),
  • Cytomegalovirus Epstein Barr virus, Varicella Zoster Virus, Human Herpesvirus 7, Human Herpesvirus 8, Influenza virus, Parainfluenza virus, Rubella virus, Mumps virus, Morbillivirus, Measles virus, Respiratory Syncytial virus, Papillomaviruses, JC virus (Polyomavirus), BK virus (Polyomavirus), Parvovirus, Coxsackie virus (A and B), Hepatitis A virus, Polioviruses, Rhinoviruses, Reovirus, Rabies Virus (Lyssavirus), Human Immunodeficiency virus 1 and 2, Human T-cell Leukemia virus.
  • viral infections include Adenovirus acute respiratory disease, Lassa fever, Astrovirus enteritis, Hantavirus pulmonary syndrome, Rift valley fever, Hepatitis E, diarrhoea, Ebola hemorrhagic fever, Marburg hemorrhagic fever, Japanese encephalitis, Dengue fever, Yellow fever, Hepatitis C, Hepatitis G, Hepatitis B, Hepatitis D, Cold sores, Genital sores, Cytomegalovirus infection, Mononucleosis, Chicken Pox, Shingles, Human Herpesvirus infection 7, Kaposi Sarcoma, Influenza, Brochiolitis, German measles, Mumps, Measles (rubeola), Measles, Brochiolitis, Papillomas (Warts), cervical cancer, Progressive multifocal leukoencephalopathy, Kidney disease, Erythema infectiosum, Viral myocarditis, meninigitis, entertitis, Hepatititi
  • the glucocorticoid receptor is a member of the steroid hormone nuclear receptor family which includes glucocorticoid receptors (GR), androgen receptors (AR), mineralocorticoid receptors (MR), estrogen receptors (ER), and progesterone receptors (PR).
  • Glucocorticoid receptors bind glucocorticoids such as Cortisol, corticosterone, and cortisone.
  • Immunosuppression refers to impairment of any component of the immune system resulting in decreased immune function. This impairment may be measured by any conventional means including whole blood assays of lymphocyte function, detection of lymphocyte proliferation and assessment of the expression of T cell surface antigens.
  • the antisheep red blood cell (SRBC) primary (IgM) antibody response assay (usually referred to as the plaque assay) is one specific method. This and other methods are described in Luster, M.I., Portier, C, Pait, D. G., White, K.L., Jr., Gennings, C, Munson, A. E., and Rosenthal, GJ. (1992).
  • a patient in need of immunosuppression is within the judgment of a physician, and can include patients with immune or inflammatory disorders.
  • patients that have undergone or will be undergoing an organ, tissue, bone marrow, or stem cell transplantation are in need of immunosuppression to prevent inflammation and/or rejection of the transplanted organ or tissue.
  • the term "immune disorder” and like terms means a disease, disorder or condition caused by the immune system of an animal, including autoimmune disorders.
  • Immune disorders include those diseases, disorders or conditions that have an immune component and those that are substantially or entirely immune system-mediated.
  • Autoimmune disorders are those wherein the animal's own immune system mistakenly attacks itself, thereby targeting the cells, tissues, and/or organs of the animal's own body.
  • the autoimmune reaction is directed against the nervous system in multiple sclerosis and the gut in Crohn's disease.
  • systemic lupus erythematosus affected tissues and organs may vary among individuals with the same disease.
  • autoimmune disorders that may be ameliorated using the compounds and methods of this invention include without limitation, autoimmune disorders of the nervous system (e.g., multiple sclerosis, myasthenia gravis, autoimmune neuropathies such as
  • autoimmune disorders of the blood e.g., autoimmune hemolytic anemia, pernicious anemia, and autoimmune thrombocytopenia
  • autoimmune disorders of the blood vessels e.g., temporal arteritis, anti-phospholipid syndrome, vasculitides such as Wegener's granulomatosis, and Behcet's disease
  • autoimmune disorders of the skin e.g., psoriasis, dermatitis herpetiformis, pemphigus vulgaris, and vitiligo
  • autoimmune disorders of the gastrointestinal system e.g., Crohn's disease, ulcerative colitis, primary biliary cirrhosis, and autoimmune hepatitis
  • autoimmune disorders of the endocrine glands e.g., Type 1 or immune-mediated diabetes mellitus, Grave's disease.
  • Hashimoto's thyroiditis, autoimmune oophoritis and orchitis, and autoimmune disorder of the adrenal gland include connective tissue and musculoskeletal system diseases) (e.g., rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis, dermatomyositis, spondyloarthropathies such as ankylosing spondylitis, and Sjogren's syndrome).
  • connective tissue and musculoskeletal system diseases e.g., rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis, dermatomyositis, spondyloarthropathies such as ankylosing spondylitis, and Sjogren's syndrome.
  • other immune system mediated diseases such as graft-versus-host disease and allergic disorders, are also included in the definition of immune disorders
  • Treatment of an immune disorder refers to administering a compound represented by any of the formulas disclosed herein to a subject, who has an immune disorder, a symptom of such a disease or a predisposition towards such a disease, with the purpose to cure, relieve, alter, affect, or prevent the autoimmune disorder, the symptom of it, or the predisposition towards it.
  • allergic disorder means a disease, condition or disorder associated with an allergic response against normally innocuous substances. These substances may be found in the environment (such as indoor air pollutants and aeroallergens) or they may be non-environmental (such as those causing dermatological or food allergies). Allergens can enter the body through a number of routes, including by inhalation, ingestion, contact with the skin or injection (including by insect sting). Many allergic disorders are linked to atopy, a predisposition to generate the allergic antibody IgE. Because IgE is able to sensitize mast cells anywhere in the body, atopic individuals often express disease in more than one organ.
  • allergic disorders include any hypersensitivity that occurs upon re-exposure to the sensitizing allergen, which in turn causes the release of inflammatory mediators.
  • Allergic disorders include without limitation, allergic rhinitis (e.g., hay fever), sinusitis, rhinosinusitis, chronic or recurrent otitis media, drug reactions, insect sting reactions, latex reactions, conjunctivitis, urticaria, anaphylaxis and anaphylactoid reactions, atopic dermatitis, asthma and food allergies.
  • the term "asthma” means a pulmonary disease, disorder or condition characterized by reversible airway obstruction, airway inflammation, and increased airway responsiveness to a variety of stimuli.
  • an "inflammatory disorder” means a disease, disorder or condition characterized by inflammation of body tissue or having an inflammatory component. These include local inflammatory responses and systemic inflammation.
  • inflammatory disorders include: transplant rejection, including skin graft rejection; chronic inflammatory disorders of the joints, including arthritis, rheumatoid arthritis, osteoarthritis and bone diseases associated with increased bone resorption; inflammatory bowel diseases such as ileitis, ulcerative colitis, Barrett's syndrome, and Crohn's disease; inflammatory lung disorders such as asthma, adult respiratory distress syndrome, and chronic obstructive airway disease; inflammatory disorders of the eye including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis; chronic inflammatory disorders of the gums, including gingivitis and periodontitis; tuberculosis; leprosy; inflammatory diseases of the kidney including uremic complications, glomerulonephritis and nephrosis; inflammatory disorders of the skin including sclerodermatitis, psoriasis and eczema; inflammatory diseases of the central nervous system, including chronic demy
  • a systemic inflammation of the body exemplified by gram-positive or gram negative shock, hemorrhagic or anaphylactic shock, or shock induced by cancer chemotherapy in response to pro-inflammatory cytokines, e.g., shock associated with pro-inflammatory cytokines.
  • shock can be induced, e.g., by a chemotherapeutic agent used in cancer chemotherapy.
  • Treatment of an inflammatory disorder refers to administering a compound or a composition of the invention to a subject, who has an inflammatory disorder, a symptom of such a disorder or a predisposition towards such a disorder, with the purpose to cure, relieve, alter, affect, or prevent the inflammatory disorder, the symptom of it, or the predisposition towards it.
  • Topoisomerase II is enzymes present in all cells that catalyze topological changes in DNA. Topoisomerase II (“topo II”) plays important roles in DNA replication, chromosome segregation and the maintenance of the nuclear scaffold in eukaryotic cells. The enzyme acts by creating breaks in DNA, thereby allowing the DNA strands to unravel and separate. Due to the important roles of the enzyme in dividing cells, the enzyme is a highly attractive target for chemotherapeutic agents, especially in human cancers. The inhibition of topo II can be determined by any method known in the art such as that described in Gadelle, D., et ai, Biochemical Pharmacology, (2006), doi:10.1016/j.bcp.2006.07.040.
  • the term "pharmaceutically acceptable salt,” is a salt formed from, for example, an acid and a basic group of one of the compounds of formula (I) - (XXXVI) or Table 1 or 2.
  • Illustrative salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, besylate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, /?-toluenesulfonate
  • pharmaceutically acceptable salt also refers to a salt prepared from a compound of formula (I) - (XXXVI) or Table 1 or 2 having an acidic functional group, such as a carboxylic acid functional group, and a pharmaceutically acceptable inorganic or organic base.
  • Suitable bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metal such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, and organic amines, such as unsubstituted or hydroxy-substituted mono-, di-, or trialkylamines; dicyclohexylamine; tributyl amine; pyridine; N- methyljN-ethylamine; diethylamine; triethyl amine; mono-, bis-, or tris-(2-hydroxy- lower alkyl amines), such as mono-, bis-, or tris-(2-hydroxyethyl)amine, 2-hydroxy- tert-butylamine, or tris-(hydroxymethyl)methylamine, N, N,-di-lower alkyl-N-
  • (hydroxy lower alkyl)-amines such as N,N-dimethyl-N-(2-hydroxyethyl)amine, or tri-(2-hydroxyethyl)amine; N-methyl-D-glucamine; and amino acids such as arginine, lysine, and the like.
  • pharmaceutically acceptable salt also refers to a salt prepared from a compound of formula (I) - (XXXVI) or Table 1 or 2 having a basic functional group, such as an amine functional group, and a pharmaceutically acceptable inorganic or organic acid.
  • Suitable acids include, but are not limited to, hydrogen sulfate, citric acid, acetic acid, oxalic acid, hydrochloric acid (HCl), hydrogen bromide (HBr), hydrogen iodide (HI), nitric acid, hydrogen bisulfide, phosphoric acid, lactic acid, salicylic acid, tartaric acid, bitartratic acid, ascorbic acid, succinic acid, maleic acid, besylic acid, fumaric acid, gluconic acid, glucaronic acid, formic acid, benzoic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, and/7-toluenesulfonic acid.
  • solvate is a solvate formed from the association of one or more pharmaceutically acceptable solvent molecules to one of the compounds of formula (I) - (XXXVI) or Table 1 or 2.
  • solvate includes hydrates (e.g., hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate, and the like).
  • a pharmaceutically acceptable carrier may contain inert ingredients which do not unduly inhibit the biological activity of the compounds.
  • the pharmaceutically acceptable carriers should be biocompatible, i.e., non-toxic, noninflammatory, non-immunogenic and devoid of other undesired reactions upon the administration to a subject. Standard pharmaceutical formulation techniques can be employed, such as those described in Remington's Pharmaceutical Sciences, ibid.
  • Suitable pharmaceutical carriers for parenteral administration include, for example, sterile water, physiological saline, bacteriostatic saline (saline containing about 0.9% mg/ml benzyl alcohol), phosphate-buffered saline, Hank's solution, Ringer's-lactate and the like.
  • Methods for encapsulating compositions (such as in a coating of hard gelatin or cyclodextran) are known in the art (Baker, et al, "Controlled Release of Biological Active Agents", John Wiley and Sons, 1986).
  • the term "effective amount” refers to an amount of a compound of this invention which is sufficient to reduce or ameliorate the severity, duration, progression, or onset of a disease or disorder, e.g. a proliferative disorder, prevent the advancement of a disease or disorder, e.g. a proliferative disorder, cause the regression of a disease or disorder, e.g. a proliferative, prevent the recurrence, development, onset or progression of a symptom associated with a disease or disorder, e.g. a proliferative disorder, or enhance or improve the prophylactic or therapeutic effect(s) of another therapy.
  • the precise amount of compound administered to a subject will depend on the mode of administration, the type and severity of the disease or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of cell proliferation, and the mode of administration. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
  • an "effective amount" of the second agent will depend on the type of drug used. Suitable dosages are known for approved agents and can be adjusted by the skilled artisan according to the condition of the subject, the type of condition(s) being treated and the amount of a compound of the invention being used. In cases where no amount is expressly noted, an effective amount should be assumed.
  • the invention provides a method of preventing, treating, managing, or ameliorating a disease or disorder, e.g. a proliferative disorder or one or more symptoms thereof, said methods comprising administering to a subject in need thereof a dose of at least 150 ⁇ g/kg, preferably at least 250 ⁇ g/kg, at least 500 ⁇ g/kg, at least 1 mg/kg, at least 5 mg/kg, at least 10 mg/kg, at least 25 mg/kg, at least 50 mg/kg, at least 75 mg/kg, at least 100 mg/kg, at least 125 mg/kg, at least 150 mg/kg, or at least 200 mg/kg or more of one or more compounds of the invention once every day, preferably, once every 2 days, once every 3 days, once every 4 days, once every 5 days, once every 6 days, once every 7 days, once every 8 days, once every 10 days, once every two weeks, once every three weeks, or once
  • dosages of a chemotherapeutic agents other than compounds of the invention which have been or are currently being used to prevent, treat, manage, or ameliorate a proliferative disorder, or one or more symptoms thereof, can be used in the combination therapies of the invention.
  • the recommended dosages of agents currently used for the prevention, treatment, management, or amelioration of a proliferative disorder, or one or more symptoms thereof can obtained from any reference in the art including, but not limited to, Hardman et al, eds., 1996, Goodman & Gilman's The Pharmacological Basis Of Basis Of Therapeutics 9 th Ed, Mc-Graw-Hill, New York; Physician's Desk Reference (PDR) 57 th Ed., 2003, Medical Economics Co., Inc., Montvale, NJ, which are incorporated herein by reference in its entirety.
  • the terms “treat”, “treatment” and “treating” refer to the reduction or amelioration of the progression, severity and/or duration of a disease or disorder, e.g. a proliferative disorder, or the amelioration of one or more symptoms (preferably, one or more discernible symptoms) of a disease or disorder, e.g. a proliferative disorder resulting from the administration of one or more therapies ⁇ e.g., one or more therapeutic agents such as a compound of the invention).
  • the terms “treat”, “treatment” and “treating” refer to the amelioration of at least one measurable physical parameter of a disease or disorder, e.g. a proliferative disorder, such as growth of a tumor, not necessarily discernible by the patient.
  • the terms “treat”, “treatment” and “treating” refer to the inhibition of the progression of a disease or disorder, e.g. a proliferative disorder, either physically by, e.g., stabilization of a discernible symptom, physiologically by, e.g., stabilization of a physical parameter, or both.
  • the terms “treat”, “treatment” and “treating” refer to the reduction or stabilization of tumor size or cancerous cell count.
  • “treatment” include “prophylaxys”. As used herein, “prophylaxys" of a disorder include reducing likelihood of developing such a disorder.
  • a compound of the invention is administered as a preventative measure to a patient, preferably a human, having a genetic predisposition to any of the disorders described herein.
  • a therapeutic agent refers to any agent(s) which can be used in the treatment, management, or amelioration of a disease or disorder, e.g. a proliferative disorder or one or more symptoms thereof.
  • the term “therapeutic agent” refers to a compound of the invention.
  • the term “therapeutic agent” refers does not refer to a compound of the invention.
  • a therapeutic agent is an agent which is known to be useful for, or has been or is currently being used for the treatment, management, prevention, or amelioration a disease or disorder, e.g. a proliferative disorder or one or more symptoms thereof.
  • the term "synergistic” refers to a combination of a compound of the invention and another therapy (e.g., a prophylactic or therapeutic agent), which is more effective than the additive effects of the therapies.
  • a synergistic effect of a combination of therapies permits the use of lower dosages of one or more of the therapies and/or less frequent administration of said therapies to a subject with a disease or disorder, e.g. a proliferative disorder.
  • a therapy e.g., a prophylactic or therapeutic agent
  • a synergistic effect can result in improved efficacy of agents in the prevention, management or treatment of a disease or disorder, e.g. a proliferative disorder.
  • a synergistic effect of a combination of therapies may avoid or reduce adverse or unwanted side effects associated with the use of either therapy alone.
  • side effects encompasses unwanted and adverse effects of a therapy (e.g., a prophylactic or therapeutic agent). Side effects are always unwanted, but unwanted effects are not necessarily adverse. An adverse effect from a therapy (e.g., prophylactic or therapeutic agent) might be harmful or uncomfortable or risky. Side effects include, but are not limited to fever, chills, lethargy, gastrointestinal toxicities (including gastric and intestinal ulcerations and erosions), nausea, vomiting, neurotoxicities, nephrotoxicities, renal toxicities
  • hepatic toxicities including elevated serum liver enzyme levels
  • myelotoxicities including leukopenia, myelosuppression, thrombocytopenia and anemia
  • dry mouth metallic taste, prolongation of gestation, weakness, somnolence, pain (including muscle pain, bone pain and headache), hair loss, asthenia, dizziness, extra-pyramidal symptoms, akathisia, cardiovascular disturbances and sexual dysfunction.
  • the term "in combination” refers to the use of more than one therapies (e.g., one or more prophylactic and/or therapeutic agents).
  • the use of the term “in combination” does not restrict the order in which therapies (e.g., prophylactic and/or therapeutic agents) are administered to a subject with a disease or disorder, e.g. a proliferative disorder.
  • a first therapy e.g., a prophylactic or therapeutic agent such as a compound of the invention
  • a first therapy can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapy (e.g., a prophylactic or therapeutic agent such as an anti-cancer agent) to a subject with a disease or disorder, e.g. a proliferative disorder, such as cancer.
  • a second therapy
  • therapies can refer to any protocol(s), method(s), and/or agent(s) that can be used in the prevention, treatment, management, or amelioration of a disease or disorder, e.g. a proliferative disorder or one or more symptoms thereof.
  • a “protocol” includes dosing schedules and dosing regimens.
  • the protocols herein are methods of use and include prophylactic and therapeutic protocols.
  • a subject is administered one or more therapies (e.g., one or more prophylactic or therapeutic agents) to "manage” a disease so as to prevent the progression or worsening of the disease.
  • therapies e.g., one or more prophylactic or therapeutic agents
  • composition that "substantially" comprises a compound means that the composition contains more than about 80% by weight, more preferably more than about 90% by weight, even more preferably more than about 95% by weight, and most preferably more than about 97% by weight of the compound.
  • a reaction that is "substantially complete” means that the reaction contains more than about 80% by weight of the desired product, more preferably more than about 90% by weight of the desired product, even more preferably more than about 95% by weight of the desired product, and most preferably more than about 97% by weight of the desired product.
  • a racemic mixture means about 50% of one enantiomer and about 50% of is corresponding enantiomer relative to a chiral center in the molecule.
  • the invention encompasses all enantiomerically-pure, enantiomerically-enriched, diastereomerically pure, diastereomerically enriched, and racemic mixtures of the compounds of the invention.
  • Enantiomeric and diastereomeric mixtures can be resolved into their component enantiomers or diastereomers by well known methods, such as chiral- phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent.
  • Enantiomers and diastereomers can also be obtained from diastereomerically- or enantiomerically-pure intermediates, reagents, and catalysts by well known asymmetric synthetic methods.
  • the compounds of the invention are defined herein by their chemical structures and/or chemical names.
  • the chemical structure is determinative of the compound's identity.
  • the compounds of the invention are administered in isolated form or as the isolated form in a pharmaceutical composition.
  • isolated means that the compounds of the invention are separated from other components of either (a) a natural source, such as a plant or cell, preferably bacterial culture, or (b) a synthetic organic chemical reaction mixture.
  • the compounds of the invention are purified via conventional techniques.
  • purified means that when isolated, the isolate contains at least 95%, preferably at least 98%, of a compound of the invention by weight of the isolate either as a mixture of stereoisomers or as a diastereomeric or enantiomeric pure isolate.
  • a composition that is "substantially free” of a compound means that the composition contains less than about 20% by weight, more preferably less than about 10% by weight, even more preferably less than about 5% by weight, and most preferably less than about 3% by weight of the compound.
  • the present invention provides compounds having formula (I) as described above or a tautomer, pharmaceutically acceptable salt, solvate, clathrate or a prodrug thereof.
  • Ri is -OH, -SH, -NR 7 H, -OR 26 , -SR 26 , -NHR 26 , -O(CH 2 ) m OH, -O(CH 2 ) m SH, -O(CH 2 ) m NR 7 H, -S(CH 2 ) m OH, -S(CH 2 ) m SH, -S(CH 2 ) m NR 7 H, -OC(O)NR 10 Ri i, -SC(O)NR 10 Ri 1 , -NR 7 C(O)NR 10 RH, -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -NR 7 C(O)OR 7 , -OCH 2 C(O)R 7 , -SCH 2 C(O)R 7 , -NR 7 CH 2 C(O)
  • R 1 is -OH, -SH, -NHR 7 , -OC(O)NR 10 R 11 , -SC(O)NR 10 R 11, -OC(O)R 7 , -SC(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -OS(O)pR 7 , -S(O) P OR 7 , -SS(O) P R 7, -OS(O) P OR 7 , -SS(O) P OR 7 , -OC(S)R 7 , -SC(S)R 7 , -OC(S)OR 7 , -SC(S)OR 7 , -OC(S)NR 10 Ri i, -SC(S)NR 10 Ri i, -OC(NR 8 )R 7 , -SC(NR 8 )R 7 , -OC(NR 8 )OR 7 , -SC(NR 8 )OR 7 , -OP(O)
  • R 3 is -OH, -SH, -NR 7 H, -NHR 26 , -O(CH 2 ) m OH, -O(CH 2 ) m SH, -O(CH 2 ) m NR 7 H, -S(CH 2 ) m OH, -S(CH 2 ) m SH, -S(CH 2 ) m NR 7 H, -OC(O)NR 10 R, ,, -SC(O)NR 10 R 1 ,, -NR 7 C(O)NR 10 Rn, -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -NR 7 C(O)OR 7 , -OCH 2 C(O)R 7 , -SCH 2 C(O)R 7 , -NR 7 CH 2 C(O)R 7 , -OCH 2 C(O
  • -OR 26 and -SR 26 are additional values for R 3 .
  • R 3 is -OH, -SH, -NHR 7 , -OC(O)NRi 0 Ri 1 , -SC(O)NRi 0 R 11 , -OC(O)R 7 , -SC(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -OS(O)pR 7 , -S(O) P OR 7 , -SS(O) P R 7 , -OS(O) P OR 7; -SS(O)pOR 7 , -OC(S)R 7 , -SC(S)R 7, -OC(S)OR 7, -SC(S)OR 7 , -OC(S)NR 10 R 1 , , -SC(S)NR 10 R 11 , -OC(NR 8 )R 7, -SC(NR 8 )R 7, -OC(NR 8 )OR 7 , -SC(NR 8 )OR 7 , -OP(O
  • R 6 for each occurrence, is independently an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, halo, cyano, nitro, guanadino, a haloalkyl, a heteroalkyl, alkoxy, haloalkoxy, -NR 10 R 1 1 , -OR 7 , -C(O)R 7 , -C(O)OR 7 , -C(S)R 7 , -C(O)SR 7 , -C(S)SR 7 , -C(S)OR 7 , -C(S)NR 10 R 11 , -C(NR 8
  • R 6 for each occurrence is independently an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, cyano, halo, nitro, an optionally substituted cycloalkyl, haloalkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, -OR 7 , -SR 7 , -NRi 0 R 11 , -OC(O)NR 10 R,,, -SC(O)NR 10 Rn, -NR 7 C(O)NRi 0 Rn, -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -NR 7 C(O)OR 7 , -OCH 2 C(O)
  • R 6 for each occurrence is independently a C1-C6 alkyl, a C1-C6 haloalkyl, a C1-C6 alkoxy, a C1-C6 haloalkoxy, a C1-C6 alkyl sulfanyl or a C3-C6 cycloalkyl. Even more preferably, R 6 for each occurrence, is independently cyclopropyl or isopropyl;
  • R 7 and R 8 for each occurrence, is independently, -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl.
  • R 7 and R 8 for each occurrence, is independently -H, Cl- C3 alkyl, C1-C6 cycloalkyl, an optionally substituted aryl or an optionally substituted heteroaryl. More preferably, R 7 and R 8 , for each occurrence, is independently -H or C1-C3 alkyl.
  • Rio and Ru for each occurrence, is independently -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl.
  • Rio and Rn for each occurrence, is independently -H, C1-C3 alkyl, C1-C6 cycloalkyl, an optionally substituted aryl or an optionally substituted heteroaryl. More preferably, Rio and Rn, for each occurrence, is independently -H or C1-C3 alkyl.
  • Rio and Rn taken together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl or an optionally substituted heteroaryl.
  • Rio and Rn taken together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, piperidinyl, piperazinyl, tetrahydroisoquinolinyl, morpholinyl or pyrazolyl.
  • R 25 for each occurrence is independently an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, halo, cyano, nitro, guanadino, a haloalkyl, a heteroalkyl, alkoxy, haloalkoxy, -NR 10 R n , -OR 7 , -C(O)R 7 , -C(O)OR 7 , -C(S)R 7 , -C(O)SR 7 , -C(S)SR 7 , -C(S)OR 7 , -C(S)NR 10 Rn, -C(NR 8 )
  • R 25 for each occurrence is independently -OH, -SH, -NHR 7 , -(CH 2 ) k OH, -(CH 2 ) k SH, -(CH 2 ) k NR 7 H, -OCH 3 , -SCH 3 , -NHCH 3 , -OCH 2 CH 2 OH, -OCH 2 CH 2 SH, -OCH 2 CH 2 NR 7 H, -SCH 2 CH 2 OH, -SCH 2 CH 2 SH, -SCH 2 CH 2 NR 7 H, -OC(O)NR 10 R 11 , -SC(O)NR 10 Rn, -NR 7 C(O)NR 10 R n , -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -SC(O)OR 7 , -NR 7 C(O)OR 7 , -SC
  • R 25 for each occurrence is independently -OH, -SH, -NHR 7 , -OC(O)NR 10 R 11, -SC(O)NR 10 R 11, -OC(O)R 7, -SC(O)R 7, -OC(O)OR 7 , -SC(O)OR 7 , -OS(O) P R 7, -S(O) P OR 7 , -SS(O)pR 7 , -OS(O) P OR 7, -SS(O) P OR 7 , -OC(S)R 7 , -SC(S)R 7 , -OC(S)OR 7 , -SC(S)OR 7 , -OC(S)NR 10 R 11 , -SC(S)NR 10 R n , -OC(NR 8 )R 7 , -SC(NR 8 )R 7 , -OC(NR 8 )OR 7 ,
  • R 25 for each occurrence is independently -SH or -OH;
  • R 26 is a Cl-C6 alkyl;
  • R 3O for each occurrence is independently an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, halo, cyano, nitro, guanadino, a haloalkyl, a heteroalkyl, alkoxy, haloalkoxy, -NR 10 Rn, -OR 7 , -C(O)R 7
  • R 30 for each occurrence is independently an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, cyano, halo, nitro, an optionally substituted cycloalkyl, haloalkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, -OR 7 , -SR 7 , -NRi 0 Rn, -OC(O)NR 10 R 1 I, -SC(O)NR 10 R 11 , -NR 7 C(O)NR 10 R 11 , -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -NR 7 C(O)OR 7 , -OCH 2 C(O)R
  • R 30 for each occurrence is independently a hydrogen, -OH, -SH, halogen, cyano, a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or C1-C6 alkyl sulfanyl. Even more preferably, R 30 for each occurrence, is independently a hydrogen, methyl, ethyl, propyl, isopropyl, methoxy or ethoxy;
  • R 35 is -H, a C1-C4 alkyl or a C1-C4 acyl;
  • R a and R b for each occurrence, is independently -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl or heteroaryl, an optionally substituted aralkyl.
  • R a and R b for each occurrence is independently a hydrogen, a C1-C6 straight or branched alkyl, optionally substituted by -OH, -CN, -SH, amino, a C1-C6 alkoxy, alkylsulfanyl, alkylamino, dialkylamino or a cycloalkyl. More preferably, R a and R for each occurrence, is independently a hydrogen, methyl, ethyl, propyl, isopropyl; Alternatively, R a and R b , taken together with the nitrogen to which they are attached, form an optionally substituted heteroaryl or heterocyclyl.
  • R a and R b taken together with the nitrogen to which they are attached form a substituted or unsubstituted nonaromatic, nitrogen-containing heterocyclyl. More preferably, R a and R b taken together with the nitrogen to which they are attached, are:
  • k is 1, 2, 3 or 4;.
  • p for each occurrence, is independently, 0, 1 or 2;
  • m for each occurrence, is independently, 1 , 2, 3 or 4;
  • n and q for each occurance is independently an integer from 0 to 4.
  • n and q for each occurance is independently 0, 1 , or 2. More preferably n and q for each occurance, is independently 0 or 1 ; and x is 0 or 1, provided that n+x is less than or equal to 4.
  • R 6 , R 25 and R 30 are independently an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, halo, cyano, nitro, guanadino, a haloalkyl, a heteroalkyl, alkoxy, haloalkoxy, -NRi 0 Ri i, -OR 7 , -C(O)R 7 , -C(O)OR 7 , -C(S)R 7 , -C(O)SR 7 , -C
  • R 6 and R 30 are as just described and R 25 is -OH, -SH, -NHR 7 , -(CH 2 ) k OH, -(CH 2 ) k SH, -(CH 2 ) k NR 7 H, -OCH 3 , -SCH 3 , -NHCH 3 , -OCH 2 CH 2 OH, -OCH 2 CH 2 SH, -OCH 2 CH 2 NR 7 H, -SCH 2 CH 2 OH, -SCH 2 CH 2 SH, -SCH 2 CH 2 NR 7 H, -OC(O)NRi 0 R 11 ,
  • the present invention provides compounds represented by structural formula (VI): or 1
  • the present invention provides compounds represented by structural formula (VII): or 1 (VII) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate or a prodrug thereof.
  • R 30 is an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, cyano, halo, nitro, an optionally substituted cycloalkyl, haloalkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, -OR 7 , -SR 7 , -NR1 0 R1 1 , -OC(O)NR 10 Ri 1, -SC(O)NR 10 R I I , -NR 7 C(O)NR 10 RH, -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -NR 7 C(O)OR 7 , -OCH 2 C(O)R 7 , -SCH 2 C
  • R 6 is an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, cyano, halo, nitro, an optionally substituted cycloalkyl, haloalkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, -OR 7 , -SR 7 , -NR 1O R 115 -OC(O)NR 1O R 1 I, -SC(O)NR 10 Rn, -NR 7 C(O)NRi 0 Rn, -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC
  • the present invention provides compounds represented by a structural formula selected from (VIII) and (IX)
  • R 1 , R 3 or R 25 are each independently -OH, -SH, -NHR 7 , -OC(O)NRi 0 Ri i , -SC(O)NRi 0 Ri i, -OC(O)R 7 , -SC(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -OS(O) P R 7 , -S(O) P OR 7 , -SS(O) p R 7 , -OS(O) p OR 7 , -SS(O) P OR 7, -OC(S)R 7 , -SC(S)R 7 , -OC(S)OR 7 , -SC(S)OR 7 , -OC(S)NR 10 Ri i, -SC(S)NR I0 R H , -OC(NR 8 )R 7 , -SC(NR 8 )R 7 , -OC(NR 8 )OR 7, -SC(
  • Rj, R 3 and R 25 are as described in the immediately preceeding two paragraphs: and
  • R a and R b are each independently a hydrogen, a C1-C6 straight or branched alkyl, optionally substituted by -OH, -CN, -SH, amino, a C1-C6 alkoxy, alkylsulfanyl, alkylamino, dialkylamino or a cycloalkyl; or R a and R b taken together with the nitrogen to which they are attached form a substituted or unsubstituted nonaromatic, nitrogen-containing heterocyclyl; and the values and preferred values for the remainder of the variables are as described above for formula (IV) formula (VII).
  • R 6 is a second more preferred embodiment for formulas (VIII) and (IX).
  • Ri and R 3 are each, independently, -OH, -SH, or -NHR 7 ;
  • R 6 is a C1-C6 alkyl, a C1-C6 haloalkyl, a C1-C6 alkoxy, a C1-C6 haloalkoxy, a C1-C6 alkyl sulfanyl or a C3-C6 cycloalkyl;
  • R 25 is -OH, -SH, -NHR 7 , -OC(O)NRi 0 Ri ,, -SC(O)NR 10 R I I , -OC(O)R 7 , -SC(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -OS(O) P R 7 , -S(O) P OR 7 , -SS(O)pR 7 , -OS(O)pOR 7 , -SS(O)pOR 7 , -OC(S)R 7 , -SC(S)R 7 , -OC(S)OR 7 , -SC(S)OR 7 , -OC(S)NRi 0 Ri, , -SC(S)NR I0 R, , , -OC(NR 8 )R 7 , -SC(NR 8 )R 7 , -OC(NR 8 )OR 7 , -SC(NR 8 )OR
  • R 30 is -OH, -SH, halogen, cyano, a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or C1-C6 alkyl sulfanyl.
  • R 30 is methyl, ethyl, propyl, isopropyl, methoxy or ethoxy;
  • R a and R b are each independently a hydrogen, a C1-C6 straight or branched alkyl, optionally substituted by -OH, -CN, -SH, amino, a C1-C6 alkoxy, alkylsulfanyl, alkylamino, dialkylamino or a cycloalkyl; or R a and R b taken together with the nitrogen to which they are attached form a substituted or unsubstituted nonaromatic, nitrogen-containing heterocyclyl; and the values and preferred values for the remainder of the variables are as described above for formula (VII).
  • Ri, R 3 and R 25 for each occurance is independently -SH or -OH;
  • R 6 is cyclopropyl or isopropyl.; and the remainder of the variables are as desribed for the third more preferred embodiment for formulas (VIII) and (IX). More preferably R 30 is methyl,ethyl, propyl, isopropyl, methoxy or ethoxy. Even more preferably, R 30 is methyl, ethyl, propyl, isopropyl, methoxy or ethoxy and R a and R b are each independently a hydrogen, methyl, ethyl, propyl, isopropyl, or taken together with the nitrogen to which they are attached, are:
  • R 35 is -H, a C1-C4 alkyl or a C1-C4 acyl; and the values and preferred values for the remainder of the variables are as described above for formula (VII).
  • the present invention is a compound represented by formula (IV), (VI), (VII), (VIII) or (IX), wherein R 1 , R 3 and R 25 are - SH or -OH and R 6 is cyclopropyl or isopropyl and the remainder of the variables are as described for Formula (IV), (VI), (VII), (VIII) or (IX), respectively.
  • the present invention provides compounds represented by a structural formula selected from (X) and (XI):
  • ring B is further optionally substituted with one or more substituents in addition to -NR a R b .
  • ring B is substituted with (R 30 ) q where q is 0, 1, 2, 3 or 4, preferably q is 0 or 1 ;
  • Ri is -OH, -SH, -NR 7 H, -OR 26 , -SR 26 , -NHR 26 , -O(CH 2 ) m OH, -O(CH 2 ) m SH, -O(CH 2 ) m NR 7 H, -S(CH 2 ) m OH, -S(CH 2 ) m SH, -S(CH 2 )JNfR 7 H, -OC(O)NR 10 R 11 , -SC(O)NR 10 R H , -NR 7 C(O)NR 10 R 11 , -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -NR 7 C(O)OR 7 , -OCH 2 C(O)R 7 , -SCH 2 C(O)R 7 , -NR 7 CH 2 C(O)R 7
  • R 1 is -OH, -SH, -HNR 7 , -OC(O)NRi 0 Ri 1, -SC(O)NR 10 R 11 , -OC(O)R 7 , -SC(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -OS(O)pR 7 , -S(O) P OR 7 , -SS(O) p R 7 , -OS(O) P OR 7 , -SS(O) P OR 7, -OC(S)R 7 , -SC(S)R 7 , -OC(S)OR 7 , -SC(S)OR 7 , -OC(S)NR 10 Ru, -SC(S)NR I0 R 1 1 , -OC(NR 8 )R 7, -SC(NR 8 )R 7, -OC(NR 8 )OR 7, -SC(NR 8 )OR 7 , -OP(O)(OR 7
  • R 3 is -OH, -SH, -NR 7 H, -OR 26 , -SR 26 , -NHR 26 , -O(CH 2 ) m OH, -O(CH 2 ) m SH, -O(CH 2 ) m NR 7 H, -S(CH 2 ) m OH, -S(CH 2 ) m SH, -S(CH 2 ) m NR 7 H, -OC(O)NR 10 R 11 , -SC(O)NR 10 R 11 , -NR 7 C(O)NRi 0 R 1 1 , -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -NR 7 C(O)OR 7 , -OCH 2 C(O)R 7 , -SCH 2 C(O)R 7 , -NR 7 CH 2 C(
  • R 3 is -OH 5 -SH 5 -HNR 7 , -OC(O)NR 10 R 11 , -SC(O)NR 10 R n , -OC(O)R 7 , -SC(O)R 7, -OC(O)OR 7 , -SC(O)OR 7 , -OS(O) P R 7 , -S(O) P OR 7 , -SS(O) P R 7 , -OS(O) P OR 7 , -SS(O) P OR 7> -OC(S)R 7 , -SC(S)R 7 , -OC(S)OR 7 , -SC(S)OR 7 , -OC(S)NRi 0 R 11 , -SC(S)NR 10 R 11 , -OC(NR 8 )R 7 , -SC(NR 8 )R 7 , -OC(NR 8 )OR 7 , -SC(NR 8 )OR 7 , -SC(NR
  • R 6 for each occurrence, is independently an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, halo, cyano, nitro, guanadino, a haloalkyl, a heteroalkyl, alkoxy, haloalkoxy, -NR 10 Rn, -OR 7 , -C(O)R 7 , -C(O)OR 7 , -C(S)R 7 , -C(O)SR 7 , -C(S)SR 7 , -C(S)OR 7 , -C(S)NR 10 Rn, -C(NR 8 )
  • R 6 for each occurrence, is independently an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, -OH, -SH, -HNR 7 , -OC(O)NRI 0 RI i, -SC(O)NRi 0 Ri i, -OC(O)R 7 , -SC(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -SC(O)OR 7 , -OS(O) P R 7 , -S(O) P OR 7 , -SS(O) p R 7, -OS(O)pOR 7 , -SS(O)pOR 7 , -OC(S)R 7 , -SC(S)R 7 , -OC(S)OR 7 , -
  • R 6 is for each occurrence, is independently a C1-C6 alkyl, a C1-C6 haloalkyl, a C1-C6 alkoxy, a C1-C6 haloalkoxy, a C1-C6 alkyl sulfanyl or a C3-C6 cycloalkyl. Still more preferably, R 6 for each occurrence, is independently a cyclopropyl or isopropyl;
  • R 7 and R 8 for each occurrence, is independently, -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl.
  • R 7 and R 8 for each occurrence, is independently -H, Cl- C3 alkyl, C1-C6 cycloalkyl, an optionally substituted aryl or an optionally substituted heteroaryl. More preferably, R 7 and R 8 , for each occurrence, is independently -H or C 1 -C3 alkyl ;
  • Rio and Rn for each occurrence, is independently -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl.
  • Ri 0 and Rn for each occurrence, is independently -H, C1-C3 alkyl, C1-C6 cycloalkyl, an optionally substituted aryl or an optionally substituted heteroaryl.
  • Rj 0 and Rn for each occurrence, is independently -H or C1-C3 alkyl; alternatively, Ri 0 and Ri i, taken together with the nitrogen to which they are attached, form an optionally substituted heterocyclyl or an optionally substituted heteroaryl.
  • Ri 0 and Rn taken together with the nitrogen to which they are attached, form an optionally substituted imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, iosoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolidinyl, piperidinyl, mo ⁇ holinyl, pyrazinyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, pyranzinyl, thiomorpholinyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl.
  • Rio and Rn taken together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, piperidinyl, piperazinyl, tetrahydroisoquinolinyl, morpholinyl or pyrazolyl;
  • R 17 for each occurrence, is independently an alkyl or an aralkyl.
  • Ri 7 for each occurance is independently a C1-C6 alkyl;
  • R 26 is a Cl -C6 alkyl;
  • R 30 for each occurrence, is independently an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteraralkyl, halo, cyano, nitro, guanadino, a haloalkyl, a heteroalkyl, alkoxy, haloalkoxy, -H, -NR 10 Rn, -OR 7 , -C(O)R 7 , -C(O)
  • R 30 for each occurrence is independently an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, cyano, halo, nitro, an optionally substituted cycloalkyl, haloalkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, -OR 7 , -SR 7 , -NR 10 R 1 11 -OC(O)NR 10 R,,, -SC(O)NR 10 R 11 , -NR 7 C(O)NR 10 R 1 1 , -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -NR 7 C(O)OR
  • R 30 for each occurrence is independently a hydrogen, -OH, -SH, halogen, cyano, a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or C1-C6 alkyl sulfanyl. Even more preferably, R 30 for each occurrence, is independently a hydrogen, methyl, ethyl, propyl, isopropyl, methoxy or ethoxy;
  • R a and R b for each occurrence, is independently -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl or heteroaryl, an optionally substituted aralkyl.
  • R a and R b for each occurrence is independently a hydrogen, a C1-C6 straight or branched alkyl, optionally substituted by -OH, -CN, -SH, amino, a C1-C6 alkoxy, alkylsulfanyl, alkylamino, dialkylamino or a cycloalkyl. More preferably, R a and R for each occurrence, is independently a hydrogen, methyl, ethyl, propyl, isopropyl;
  • R a and R b taken together with the nitrogen to which they are attached, form an optionally substituted heteroaryl or heterocyclyl.
  • R a and R b taken together with the nitrogen to which they are attached form a substituted or unsubstituted nonaromatic, nitrogen-containing heterocyclyl. More preferably, R a and R b taken together with the nitrogen to which they are attached, are:
  • X 3 and X 4 are each, independently, N, N(O), N + (R n ), CH or CR 6 ;
  • the present invention provides a compound represented by a structural formula selected from (XII) and (XIII):
  • R 6 is for each occurrence, is independently an optionally substituted C1-C6 alkyl, an optionally substituted C3-C6 cycloalkyl, an optionally substituted C3-C6 cycloalkenyl, an optionally substituted heterocyclyl, a halo, a haloalkyl, a haloalkoxy, a heteroalkyl, an alkoxy, an alkylsulfanyl, -OH, -SH, -NHR 7 , -(CH 2 ) Ic OH, -(CH 2 ) Ic SH, -(CH 2 ) k NR 7 H, -OCH 3 , -SCH 3 , -NHCH 3 , -OCH 2 CH 2 OH, -OCH 2 CH 2 SH, -OCH 2 CH 2 NR 7 H, -SCH 2 CH 2 OH, -SCH 2 CH 2 SH, -SCH 2 CH 2 NR 7 H, -OC(O)NR 10
  • R 30 is independently an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, halo, cyano, nitro, guanadino, a haloalkyl, a heteroalkyl, alkoxy, haloalkoxy, -NRioRn, -OR 7 , -C(O)R 7 , -C(O)OR 7 , -C(S)R 7 , -C(O)SR 7 , -C(S)SR 7 , -C(S)OR 7 , -C(S)NRi 0 Rn, -C(NR 8
  • R 30 is an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, cyano, halo, nitro, an optionally substituted cycloalkyl, haloalkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, an optionally substituted heteroaralkyl, -OR 7 , -SR 7 , -NRioRn, -OC(O)NR 10 Ri i, -SC(O)NRi 0 Ri i, -NR 7 C(O)NRi 0 Ri i, -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -SC(O)OR 7 , -SC(O)OR 7 , -SC(O)OR
  • the present invention provides a compound represented by a structural formula selected from (XVI) - (XIX):
  • Ri and R 3 are each independently -OH, -SH, -HNR 7 , -OC(O)NR I0 RI i , -SC(O)NR 10 Rn, -OC(O)R 7 , -SC(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7, -OS(O) p R 7, -S(O)pOR 7 , -SS(0)pR 7 , -OS(O)pOR 7 , -SS(O) P OR 7 , -OC(S)R 7 , -SC(S)R 7, -OC(S)OR 7 , -SC(S)OR 7 , -OC(S)NR I0 R I i, -SC(S)NR 10 Ri ,, -OC(NR 8 )R 7, -SC(NR 8 )R 7 , -OC(S)R 7 , -OC(S)R 7 , -OC(S)NR I0 R
  • R 6 for each occurrence, is independently an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, -OH, -SH, -HNR 7 , -OC(O)NR I0 R I I , -SC(O)NR I0 R H , -OC(O)R 7 , -SC(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -SC(O)OR 7 , -OS(O) P R 7 , -S(O) P OR 7 , -SS(O) P R 7 , -OS(O) P OR 7 , -SS(O) P OR 7 , -SS(O) P OR 7 , -OC(S)R 7 , -SC(S)R 7 , -
  • R a and R b are each independently a hydrogen, a C1-C6 straight or branched alkyl, optionally substituted by -OH, -CN, -SH, amino, a C1-C6 alkoxy, alkylsulfanyl, alkylamino, dialkylamino or a cycloalkyl; or R a and R b taken together with the nitrogen to which they are attached form a substituted or unsubstituted nonaromatic, nitrogen-containing heterocyclyl; and the values and preferred values for the remainder of the variables are as described for formulas (XIV) and (XV). Still more preferably for formulas (XVI) - (XIX), Ri , R 3 , R 6 , R a and R b are as described in the immediately preceeding paragraphs; and
  • R 6 is a Cl -C6 alkyl, a C1-C6 haloalkyl, a C1-C6 alkoxy, a C1-C6 haloalkoxy, a C1-C6 alkyl sulfanyl or a C3-C6 cycloalkyl; and the values and preferred values for the remainder of the variables are as described above for formulas (X) and (XI). More preferably the values and preferred values for the remainder of the variables are as described above for forumulas (XIV) and (XV).
  • the present invention provides a compound represented by a structural formula selected from (XX) - (XXXVI): or 1 oorri 1 b
  • Ri and R 3 are each, independently, -OH, -SH, or -NHR 7 ; and R 3 o is -OH, -SH, halogen, cyano, a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or C1-C6 alkyl sulfanyl (preferably methyl, ethyl, propyl, isopropyl, methoxy or ethoxy).
  • Ri and R 3 for each occurance is independently -SH or -OH;
  • R 6 is cyclopropyl or isopropyl; and
  • R 30 is -OH, -SH, halogen, cyano, a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or C1-C6 alkyl sulfanyl (preferably methyl, ethyl, propyl, isopropyl, methoxy or ethoxy).
  • Ri, R 3 , R 6 and R 30 are as just described and R a and R b are each independently a hydrogen, methyl, ethyl, propyl, isopropyl, or taken together with the nitrogen to which they are attached, are:
  • R 35 is -H, a C1-C4 alkyl or a C1-C4 acyl; and the values and preferred values for the remainder of the variables are as defined for formulas (XVI)-(XIX).
  • the compounds of the present invention are represented by a structural formula selected from (II) and (III):
  • ring B is further optionally substituted with one or more substiruents in addition to -NR a R b .
  • ring B is further substituted with (R. 3 o) q where q is 0, 1, 2, 3 or 4, preferably q is 0 or 1;
  • R is -OH, -SH, -NR 7 H, -OR 26 , -SR 26 , -NHR 26 , -O(CH 2 ) m OH, -O(CH 2 ) m SH, -O(CH 2 ) m NR 7 H, -S(CH 2 ) m OH, -S(CH 2 ) m SH, -S(CH 2 ) m NR 7 H, -OC(O)NR 10 Ri i, -SC(O)NR 10 Rii, -NR 7 C(O)NR I0 R I i, -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -NR 7 C(O)OR 7 , -OCH 2 C(O)R 7 , -SCH 2 C(O)R 7 , -NR 7 CH 2 C(O)R
  • Ri is -OH, -SH, -HNR 7 , -OC(O)NR 10 R 11 , -SC(O)NRi 0 Ri i, -OC(O)R 7 , -SC(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -OS(O)pR 7 , -S(O) P OR 7 , -SS(O) P R 7, -OS(O)pOR 7 , -SS(O) P OR 7 , -OC(S)R 7 , -SC(S)R 7 , -OC(S)OR 7 , -SC(S)OR 7 , -OC(S)NRi 0 RiI, -SC(S)NRi 0 Ri i, -OC(NR 8 )R 7 , -SC(NR 8 )R 7 , -OC(NR 8 )OR 7, -SC(NR 8 )OR 7 , -SC(NR
  • R 3 is -OH, -SH, -NR 7 H, -OR 26 , -SR 26 , -NHR 26 , -0(CH 2 ) m 0H, -O(CH 2 ) m SH, -O(CH 2 ) m NR 7 H, -S(CH 2 ) m OH, -S(CH 2 ) m SH, -S(CH 2 ) m NR 7 H, -OC(O)NR 10 Ri i, -SC(O)NR 10 R 11 , -NR 7 C(O)NR 10 R 11 , -OC(O)R 7 , -SC(O)R 7 , -NR 7 C(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -NR 7 C(O)OR 7 , -OCH 2 C(O)R 7 , -SCH 2 C(O)R 7 , -NR 7 CH 2 C(O)
  • R 3 is -OH, -SH, -HNR 7 , -OC(O)NRI 0 RI i, -SC(O)NRi 0 R ⁇ i, -OC(O)R 7 , -SC(O)R 7 , -OC(O)OR 7 , -SC(O)OR 7 , -OS(O)pR 7 , -S(O)pOR 7 , -SS(O)pR 7 , -OS(O) P OR 7 , -SS(O) P OR 7 , -OC(S)R 7, -SC(S)R 7 , -OC(S)OR 7 , -SC(S)OR 7 , -OC(S)NRI 0 RI i, -SC(S)NRi 0 Ri i, -OC(NR 8 )R 7 , -SC(NR 8 )R 7 , -OC(NR 8 )OR 7 , -SC(NR 8 )OR
  • R 7 and R 8 for each occurrence, is independently, -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl.
  • R 7 and R 8 for each occurrence, is independently -H, Cl- C3 alkyl, C1-C6 cycloalkyl, an optionally substituted aryl or an optionally substituted heteroaryl. More preferably, R 7 and R 8 , for each occurrence, is independently -H or C 1 -C3 alkyl ;
  • Rio and Ru for each occurrence, is independently -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl.
  • Rio and Rn for each occurrence, is independently -H, C1-C3 alkyl, C1-C6 cycloalkyl, an optionally substituted aryl or an optionally substituted heteroaryl.
  • Rio and Rn for each occurrence, is independently -H or C1-C3 alkyl;
  • Rj 0 and Rn taken together with the nitrogen to which they are attached, form an optionally substituted imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, iosoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrazinyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, pyranzinyl, thiomorpholinyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl.
  • Rio and Rn taken together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, piperidinyl, piperazinyl, tetrahydroisoquinolinyl, mo ⁇ holinyl or pyrazolyl;
  • R 22 for each occurrence, is independently -H, an optionally substituted alky, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl, a haloalkyl, -C(O)R 7 , -C(O)OR 7 , -OC(O)R 7 , -C(O)NRi 0 R 11 , -NR 8 C(O)R 7 , -S(O)pR 7 , -S(O)pOR 7 , or -S(O) p NR 10 Rn.
  • R 22 is -H, an alkyl, an aralkyl, -C(O)R 7 ,
  • R 23 and R 24 are independently -H, an optionally substituted alky, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl, halo, cyano, nitro, guanadino, a haloalkyl, a heteroalkyl, -NR 1O Rn, -OR 7 , -C(O)R 7 , -C(O)OR 7 , -OC(O)R 7 , -C(O)NR 10 Rn, -NR 8 C(O)R 7 , -SR 7 , -S(O) P R 7 , -OS(O) 15 R 7 , -S
  • R a and R b for each occurrence, is independently -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl or heteroaryl, an optionally substituted aralkyl.
  • R a and R b for each occurrence is independently a hydrogen, a C1-C6 straight or branched alkyl, optionally substituted by -OH, -CN, -SH, amino, a C1-C6 alkoxy, alkylsulfanyl, alkylamino, dialkylamino or a cycloalkyl. More preferably, R a and R b for each occurrence, is independently a hydrogen, methyl, ethyl, propyl or isopropyl; Alternatively, R a and R b , taken together with the nitrogen to which they are attached, form an optionally substituted heteroaryl or heterocyclyl.
  • R a and R b taken together with the nitrogen to which they are attached form a substituted or unsubstituted nonaromatic, nitrogen-containing heterocyclyl. More preferably, R a and R b taken together with the nitrogen to which they are attached, are:
  • Xi 4 is O, S, or NR 7 .
  • Xi 4 is O; p, for each occurrence, is independently, O, 1 or 2; and m, for each occurrence, is independently, 1, 2, 3, or 4.
  • Ri is
  • Ri is -OH, -SH, or -NHR 7 ;
  • R 22 is -H, an alkyl, an aralkyl, -C(O)R 7 , -C(O)OR 7 , or -C(O)NR I0 R I I .
  • Ri is -OH, -SH, or -NHR 7 ;
  • R 22 is -H, an alkyl, an aralkyl, -C(O)R 7 , -C(O)OR 7 , or -C(O)NRi 0 Ri i;
  • Xi 4 is O.
  • the values and preferred values for the remainder of the variables are as described above.
  • the compound is not: benzamide, N-[4-[3-(2,4-dihydroxyphenyl)-l ,5-dihydro-5-oxo-4//-l ,2,4- triazol-4-yl]phenyl] ; benzeneacetamide, N-[4-[3-(2,4-dihydroxyphenyl)- 1 ,5-dihydro-5-oxo-4H- l,2,4-triazol-4-yl]phenyl]; benzamide, N-[4-[3-(2,4-dimethoxyphenyl)-l,5-dihydro-5-oxo-4H- 1,2,4- triazol-4-yl]phenyl]; or
  • the compound is a compound of formula (XXXVI):
  • R' l is -OH or -SH
  • R 26 is a Cl-C6 alkyl; R° and R d , for each occurrence, are independently -H, -SO 2 R 26 , C1-C6 alkyl optionally substituted with lower alkoxy, amino, lower alkyl amino, or lower dialkyl amino; or R c and R d , taken together with the nitrogen to which they are attached, form a heterocyclyl selected from the group consisting of:
  • R'i is -OH.
  • R ⁇ is -SH.
  • R c and R d are both -H, methyl, or n-propyl.
  • R c and R d are C1-C6 alkyl optionally substituted with lower alkoxy or lower dialkyl amino.
  • R c and R d taken together with the nitrogen to which they are attached, form a heterocyclyl selected from the group consisting of:
  • one of R c or R d is - SO 2 CH 3 .
  • the compound is selected from the group consisting of
  • the compound is selected from the group consisting of
  • the compound is selected from the group consisting of 5-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-mercapto-4H-l,2,4-triazol-4-yl)-
  • Exemplary compounds of the invention are depicted in Table 1 below, including tautomers, pharmaceutically acceptable salts, solvates, clathrates, hydrates, polymorphs or prodrugs thereof.
  • Exemplary compounds of the invention are depicted in Table 2 below, including tautomers, pharmaceutically acceptable salts, solvates, clathrates, hydrates, polymorphs or prodrugs thereof.
  • tautomeric forms of the disclosed compound exist, such as the tautomeric structures shown below:
  • prodrugs i.e. compounds which can be metabolized or hydrolyzed in vivo to a compound of the present invention are encompassed by the present description.
  • prodrugs i.e. compounds which can be metabolized or hydrolyzed in vivo to a compound of the present invention are encompassed by the present description.
  • the following embodiments of a compound of the present invention can be produced in vivo in the following reaction:
  • hydrolyzable protecting groups can be employed with the compounds of the present invention to obtain prodrugs encompassed by the present description.
  • solvates e.g., hydrates
  • Solvates refer to crystalline forms wherein solvent molecules are incorporated into the crystal lattice during crystallization.
  • Solvate may include water or nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and EtOAc.
  • Solvates, wherein water is the solvent molecule incorporated into the crystal lattice are typically referred to as "hydrates”. Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water.
  • the compound including solvates thereof, may exist in crystalline forms, non-crystalline forms or a mixture thereof.
  • the compounds or solvates may also exhibit polymorphism (i.e. the capacity to occur in different crystalline forms). These different crystalline forms are typically known as "polymorphs.”
  • polymorphs typically known as "polymorphs.”
  • the disclosed compounds and solvates e.g., hydrates
  • Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties.
  • Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification.
  • different polymorphs may be produced, for example, by changing or adjusting the conditions used in solidfying the compound. For example, changes in temperature, pressure, or solvent may result in different polymorphs.
  • one polymorph may spontaneously convert to another polymorph under certain conditions.
  • “Clathrate” refers to a chemical substance consisting of a lattice of one type of molecule trapping and containing a second type of molecule. Without wishing to be bound by any theory, it is believed that the compounds of the invention preferentially bind to Hsp90 in the tautomeric form shown above, and thereby inhibit the activity of Hsp90.
  • compounds of the invention can be obtained by heating a benzoic acid (1) with an aminophenyl (2) to give a phenyl benzamide (3) which can then be reacted with hydrazine to give a triazole (4) (see Scheme I below).
  • Starting materials useful for preparing compounds of the invention and intermediates therefore, are commercially available or can be prepared from commercially available materials using known synthetic methods and reagents.
  • Reactive functional groups can be protected during one or more reaction step, then deprotected to restore the original functionality.
  • suitable protecting groups for hydroxyl groups include benzyl, methoxymethyl, allyl, trimethylsilyl, tert-butyldimethylsilyl, acetate, and the like.
  • suitable amine protecting groups include benzyloxycarbonyl, tert-butoxycarbonyl, tert-butyl, benzyl and fluorenylmethyloxy-carbonyl (Fmoc).
  • suitable thiol protecting groups include benzyl, tert-butyl, acetyl, methoxymethyl and the like.
  • Other suitable protecting groups are well known to those of ordinary skill in the art and include those found in T. W. Greene, Protecting Groups in Organic Synthesis, John Wiley & Sons, Inc. 1981. Scheme I:
  • the compounds can be prepared as shown in Scheme II.
  • a dihydroxy benzoic acid methyl ester is reacted with benzyl chloride, to produce a Bis-benzyloxy benzoic acid methyl ester (1).
  • the Bis-benzyloxy benzoic acid methyl ester can then be heated with LiOH to give a Bis-benzyloxy benzoic acid (2).
  • the Bis-benzyloxy benzoic acid (2) is then reacted with an aminophenyl to produce a phenyl-benzamide (3).
  • the phenyl-benzamide (3) is then reacted with hydrazine to give a triazol (4).
  • the hydroxy groups can then be unprotecxted in the presence of palladium on charcoal to give the final product.
  • the compounds can be prepared as shown in Scheme III.
  • a nitroaniline (1) can be reacted with propionyl chloride to yield nitro-phenyl- propionamide (2).
  • NaH can then be added to a solution of (2) in anhydrous THF followed by iodomethane to give pure product nitro-phenyl-N-methyl-propionamide (3).
  • nitro-phenyl-N-methyl-propionamide (3) and borane-methyl sulfide complex are heated to give the nitro-phenyl-methyl-propyl-amine (4).
  • a solution of (4) in MeOH/EtOAc containing Pd-C can be subjected to hydrogenation to give the N-methyl-N-propyl -benzene- 1 ,3-diamine (5).
  • the isothiocyanate (6) can be reacted with the hydrazide (7) to give the intermediate (8).
  • a solution of NaOH in water can be added to the intermediate (8), which can then be flushed with nitrogen and heated.
  • the reaction mixture can then be cooled and acidified.
  • the mixture can then be filtered and purified to give 4- isopropyl-6- ⁇ 5-mercapto-4-[4-methoxy-3-(methyl-propyl-amino)-phenyl]-4H- [l,2,4]triazol-3-yl ⁇ -benzene- 1, 3 -diol.
  • the compounds can be prepared as shown in Scheme IV.
  • a bromo-nitrobenzene (1) can be reacted with N 1 , N 2 , N 2 -trimethylethane-l,2- diamine to give ⁇ -(nitrophenyO-N 7 , N 2 , ⁇ -trimethylethane-l,2-diamine (2).
  • a solution of (2) in can be subjected to hydrogenation, passed through a short pad of celite, washed with MeOH and evaporated under reduced pressure.
  • Thiocarbodiimidazole can then be added to (2) to give the N 7 -(isothiocyanato- phenyl)- )-N 7 , N 2 , N 2 -trimethylethane-l,2-diamine (3).
  • the isothiocyanate (3) can then be reacted with a benzoic acid hydrazide to give the final product 4-(4-(3-((2-(dimethylamino)ethyl)(methyl)amino)-4- methoxyphenyl)-5-mercapto-4H- 1 ,2,4-triazol-3-yl)-6-isopropylbenzene- 1 ,3-diol (4).
  • the present invention is directed to therapies which involve administering one of more compounds of the invention, and compositions comprising said compounds to a subject, preferably a human subject, to inhibit the activity of Hsp90 or to prevent, treat, manage, or ameliorate a proliferative disorder, such as cancer, or one or more symptoms thereof.
  • the invention provides a method of inhibiting the activity of
  • Hsp90 in a cell comprising administering to the cell an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the compound is administered to a cell in a subject, preferably a mammal, and more preferably a human.
  • the present invention is directed to treating cancers in which aberrant expression and/or activation of c-kit has been implicated as a contributing factor.
  • the method comprises adiministering to a patient an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the present invention is directed to treating cancers in which expression of Bcr-Abl has been implicated as a contributing factor.
  • the method comprises adiministering to a patient an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the present invention is directed to treating cancers in which aberrant expression and/or activation of flt-3 has been implicated as a contributing factor.
  • the method comprises adiministering to a patient an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the present invention is directed to treating cancers in which aberrant expression and/or activation of EGFR has been implicated as a contributing factor.
  • the method comprises adiministering to a patient an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the present invention is directed to treating cancers in which Hsp90 is over expressed compared with normal cells.
  • the method comprises adiministering to a patient an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • cancers in which Hsp90 is over expressed include difuse large B-cell lymphomas (DLBCL).
  • the invention provides a method of inhibiting the activity of
  • the compound in a cell, comprising administering to the cell an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the compound is administered to a cell in a subject, preferably a mammal, and more preferably a human.
  • the invention provides a method of treating or preventing a proliferation disorder in a mammal, comprising administering to the mammal an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the compound is administered to a human to treat or prevent a proliferative disorder.
  • the proliferation disorder is cancer.
  • the compound is administered with one or more additional therapeutic agents.
  • the additional therapeutic agent is an anticancer agent.
  • the invention provides a method for treating cancer in a mammal, comprising administering to the mammal an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the compound is administered to a human to treat or prevent cancer.
  • the compound is administered with one or more additional therapeutic agents.
  • the one or more additional therapeutic agents are anticancer agents.
  • the invention provides a method for treating a c-kit associated cancer in a mammal, comprising administering to the mammal an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the compound is administered to a human to treat or prevent the c-kit associated cancer.
  • the compound is administered with one or more additional therapeutic agents.
  • the one or more additional therapeutic agents are anticancer agents.
  • the invention provides a method for treating a Bcr-Abl associated cancer in a mammal, comprising administering to the mammal an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the compound is administered to a human to treat or prevent the Bcr-Abl associated cancer.
  • the compound is administered with one or more additional therapeutic agents.
  • the one or more additional therapeutic agents are anticancer agents.
  • the invention provides a method for treating a flt3 associated cancer in a mammal, comprising administering to the mammal an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the compound is administered to a human to treat or prevent the flt3 associated cancer.
  • the compound is administered with one or more additional therapeutic agents.
  • the one or more additional therapeutic agents are anticancer agents.
  • the invention provides a method for treating an EGFR associated cancer in a mammal, comprising administering to the mammal an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the compound is administered to a human to treat or prevent the EGFR associated cancer.
  • the compound is administered with one or more additional therapeutic agents.
  • the one or more additional therapeutic agents are anticancer agents.
  • the invention provides a method for treating a cancer in a mammal which is characterized by the upregulation of Hsp90 compared to normal cells of the same type, comprising administering to the mammal an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the compound is administered to a human to treat or prevent the cancer associated with the upregulation of Hsp90.
  • the cancer associated with the upregulation of Hsp90 is DLBCL.
  • the compound is administered with one or more additional therapeutic agents.
  • the one or more additional therapeutic agents are anticancer agents.
  • the invention provides a method for treating or inhibiting angiogenesis in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the invention provides a method of blocking, occluding, or otherwise disrupting blood flow in neovasculature, comprising contacting the neovasculature with an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the neovasculature is in a subject and blood flow in the neovasculature is blocked, occluded, or otherwise disrupted in the subject by administering to the subject an effective amount of a compound represented by any one of the formulas disclosed herein, or any embodiment thereof.
  • the subject is human.
  • the present invention is directed to therapies which involve administering one or more compounds of the invention, or compositions comprising said compounds to a subject, preferably a human subject, to inhibit the activity of Hsp90 or to prevent, treat, manage, or ameliorate an infection.
  • the invention is directed to a method of treating or preventing a fungal infection.
  • the invention is directed to a method of treating or preventing a yeast infection.
  • the invention is directed to a method of treating or preventing a yeast infection caused by a Candida yeast.
  • the invention is directed to a method of treating or preventing a bacterial infection. In another embodiment the invention is directed to a method of treating or preventing a bacterial infection caused by a Gram Positive Bacteria.
  • the invention is directed to a method of treating or preventing a bacterial infection caused by a Gram Negative Bacteria. In another embodiment the invention is directed to a method of treating or preventing a viral infection.
  • the invention is directed to a method of treating or preventing a viral infection caused by an influenza virus, a herpes virus, a hepatitis virus, or an HIV virus.
  • the invention is directed to a method of treating or preventing a viral infection caused by influenza A virus, herpes simplex virus type 1 , hepatitis C virus, hepatitis B virus, HIV-I virus, or Epstein-Barr Virus.
  • the invention is directed to a method of treating or preventing a parasitic infection. In another embodiment the invention is directed to a method of treating or preventing a protozoal infection.
  • the invention is directed to a method of treating or preventing an infection caused by plasmodium falciparum or trypsanosoma cruzi.
  • the invention is directed to a method of treating or preventing an infection caused by a leishmania protozoa.
  • the invention is directed to a method of treating or preventing an amoebic infection.
  • the invention is directed to a method of treating or preventing a helminth infection. In another embodiment the invention is directed to a method of treating or preventing an infection caused by schistostoma mansoni.
  • compounds of the invention are administered in combination with one or more additional therapeutic agents.
  • the present invention provides a method of modulating the activity of glucocorticoid receptors in a cell, comprising administering to the cell an effective amount of an Hsp90 inhibitor compound represented by any one of the formulas disclosed herein.
  • the present invention is a method of treating an inflammatory disorder in a subject in need thereof, comprising administering a compound represented by any one of the formulas disclosed herein.
  • the inflammatory disorder is selected from the group consisting of transplant rejection, skin graft rejection, arthritis, rheumatoid arthritis, osteoarthritis and bone diseases associated with increased bone resorption; inflammatory bowel disease, ileitis, ulcerative colitis, Barrett's syndrome, Crohn's disease; asthma, adult respiratory distress syndrome, chronic obstructive airway disease; corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis, endophthalmitis; gingivitis, periodontitis; tuberculosis; leprosy; uremic complications, glomerulonephritis, nephrosis; sclerodermatitis, psoriasis, eczema; chronic demyelinating diseases of the nervous system, multiple sclerosis, AIDS- related neurodegeneration, Alzheimer's disease, infectious meningitis, encephalomyelitis, Parkinson's disease, Huntington's disease,
  • the present invention is a method of treating an immune disorder in a subject in need thereof, comprising administering a compound represented by any one of the formulas disclosed herein.
  • the immune disorder is selected from the group consisting of multiple sclerosis, myasthenia gravis, Guillain-Barre, autoimmune uveitis, autoimmune hemolytic anemia, pernicious anemia, autoimmune thrombocytopenia, temporal arteritis, anti- phospholipid syndrome, vasculitides such as Wegener's granulomatosis, Behcet's disease, psoriasis, dermatitis herpetiformis, pemphigus vulgaris, vitiligo, Crohn's disease, ulcerative colitis, primary biliary cirrhosis, autoimmune hepatitis, Type 1 or immune-mediated diabetes mellitus, Grave's disease.
  • Hashimoto's thyroiditis Hashimoto's thyroiditis, autoimmune oophoritis and orchitis, autoimmune disorder of the adrenal gland, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis, dermatomyositis, ankylosing spondylitis, and Sjogren's syndrome.
  • the present invention is a method of suppressing an immune response in a subject in need thereof, comprising administering a compound represented by any one of the formulas disclosed herein, or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or a prodrug thereof.
  • the subject in need of immunosuppression is a subject that has received an organ or tissue transplant, such as a skin graft, heart, kidney, lung, liver, pancreas, cornea, bowel, stomach, and the like.
  • the subject in need of immunosuppression is a subject that has received stem cell transplantation.
  • the transplant may be a syngeneic transplant (i.e., from a donor that has the same genetic make up), an allographic transplant (i.e., from a donor of the same species) or a xenographic transplant (i.e., from a donor that is a different species).
  • a syngeneic transplant i.e., from a donor that has the same genetic make up
  • an allographic transplant i.e., from a donor of the same species
  • a xenographic transplant i.e., from a donor that is a different species.
  • the present invention is a method of inhibiting the production of inflammatory cytokines, such as G-CSF, GM-CSF, IL-12, IL-l ⁇ , IL- 23, IL-6, IL-8, and TNF- ⁇ , in a subject in need of such treatment.
  • the method comprises administering to the subject an effective amount of a compound represented by any one of the formulas disclosed herein.
  • compounds of the invention inhibit topoisomerase II.
  • topoisomerase II is associated with a disease and administering the compound will treat or prevent the disease.
  • the disease is a proliferative disease.
  • the proliferative disease is cancer.
  • the disease is an infection.
  • c-kit protects hematopoietic stem and progenitor cells from apoptosis (Lee, et al., 1997, J. Immunol, 159:3211-3219), thereby contributing to colony formation and hematopoiesis.
  • Expression of c-kit is frequently observed in acute myelocytic leukemia (AML) and sometimes observed in acute lymphocytic leukemia (ALL) (for reviews, seesperling, et al., 1997, Haemat., 52:617-621 ; Escribano, et al., 1998, Leuk. Lymph., 30:459-466).
  • c-kit is expressed in the majority of AML cells, its expression does not appear to be prognostic of disease progression (Sperling, et al, 1997, Haemat. 52:617-621). However, SCF protected AML cells from apoptosis induced by chemotherapeutic agents (Hassan, et al., 1996, Acta. Hem., 95:257-262). Therefore, degradation of c-kit caused by the inhibition of Hsp90 by the compounds of the invention will enhance the efficacy of these agents and may induce apoptosis of AML cells.
  • CML chronic myelogenous leukemia
  • GISTs are the most common mesenchymal tumor of the digestive system. More than 90% of GISTs express c-kit, which is consistent with the putative origin of these tumor cells from interstitial cells of Cajal (ICCs) (Hirota, et al, 1998, Science, 279:577-580).
  • the c-kit expressed in GISTs from several different patients was observed to have mutations in the intracellular juxtamembrane domain leading to constitutive activation (Hirota, et al., 1998, Science 279:577-580). Therefore, degradation of c-kit caused by the inhibition of Hsp90 by the compounds of the invention will be an efficacious means for the treatment of these cancers.
  • Testicular tumors develop from Leydig cells with high frequency in transgenic mice expressing human papilloma virus 16 (HPV 16) E6 and E7 oncogenes (Kondoh, et al, 1991, J. Virol, (55:3335-3339; Kondoh, et al, 1994, J. Urol, 752:2151-2154).
  • HPV 16 human papilloma virus 16
  • tumors express both c-kit and SCF, and an autocrine loop may contribute to the tumorigenesis (Kondoh, et al, 1995, Oncogene, 70:341-347) associated with cellular loss of functional p53 and the retinoblastoma gene product by association with E6 and E7 (Dyson, et al, 1989, Science, 243:934-937; Werness, et al, 1990, Science, 248:16-19; Scheffher, et al, 1990, Cell, (53:1129-1136).
  • Defective signaling mutants of SCF (Kondoh, et al, 1995, Oncogene, 70:341-347) or c-kit (Li, et al, 1996, Cane. Res., 56:4343-4346) inhibited formation of testicular tumors in mice expressing HPVl 6 E6 and E7. Since c-kit kinase activation is pivotal to tumorigenesis in these animals, the compounds of the invention which inhibit Hsp90 and thereby cause the degradation of c-kit will be useful for preventing or treating testicular tumors associated with human papilloma virus.
  • c-kit is expressed by the majority of carcinomas in situ and seminomas, but c-kit is expressed in only a minority of nonseminomas (Strohmeyer, et al, 1991, Cane. Res., 57:1811-1816; Rajpert-de Meyts, et al, 1994, Int. J. Androl, 77:85-92; Izquierdo, et al, 1995, J. Pathol, 777:253-258; Strohmeyer, et al, 1995, J. Urol, 753:511-515; Bokenmeyer, et al., 1996, J. Cance. Res., Clin.
  • SCF and c-kit are expressed throughout the central nervous system of developing rodents, and the pattern of expression suggests a role in growth, migration and differentiation of neuroectodermal cells. Expression of SCF and c-kit have also been reported in the adult brain (Hamel, et al., 1997, J. Neuro-Onc, 55:327-333). Expression of c-kit has also been observed in normal human brain tissue (Tada, et al. 1994, J.
  • Glioblastoma and astrocytoma which define the majority of intracranial tumors, arise from neoplastic transformation of astrocytes (Levin, et al, 1997, Principles & Practice of Oncology, 2022-2082). Expression of c-kit has been observed in glioblastoma cell lines and tissues (Berdel, et al., 1992, Cane. Res., 52:3498-3502; Tada, et al., 1994, J. Neuro., 50:1063-1073; Stanulla, et al., 1995, Act. Neuropath., 59:158-165).
  • the Philadelphia chromosome which generates the fusion protein Bcr-Abl is associated with the bulk of chronic myelogenous leukemia (CML) patients (more than 95%), 10-25% of acute lymphocytic leukemia (ALL) patients, and about 2-3% of acute myelogenous leukemias (AML).
  • CML chronic myelogenous leukemia
  • ALL acute lymphocytic leukemia
  • AML acute myelogenous leukemias
  • Bcr-Abl is a factor in a variety of other hematological malignancies, including granulocytic hyperplasia resembling CML, myelomonocytic leukemia, lymphomas, and erythroid leukemia (see Lugo, et al., MCB (1989), 9:1263-1270; Daley, et al., Science (1990), 247:824- 830; and Honda, Blood (1998), 91 :2067-2075, the entire teachings of each of these references are incorporated herein by reference).
  • Bcr-Abl oncoproteins such as p210 and pi 85 BCR-ABL
  • Bcr-Abl oncoproteins are causative factors in these leukemias.
  • the malignant activity is due in large part to the Bcr-Abl protein's highly activated protein tyrosine kinase activity and its abnormal interaction with protein substrates (Arlinghaus et al., In: UCLA Symposia on Molecular and Cellular Biology New Series, Acute
  • Bcr-Abl oncoprotein p210 Bcr-Abl is associated with both CML and ALL, whereas the smaller oncoprotein, pi 85 BCR-ABL, is associated with ALL patients, although some CML patients also express pi 85 (Campbell et al., 1991).
  • FLT3 associated cancers are cancers in which inappropriate FLT3 activity is detected.
  • FLT3 associated cancers include hematologic malignancies such as leukemia and lymphoma.
  • FLT3 associated cancers include acute myelogenous leukemia (AML), B-precursor cell acute lymphoblastic leukemia, myelodysplastic leukemia, T-cell acute lymphoblastic leukemia, mixed lineage leukemia (MLL), or chronic myelogenous leukemia (CML).
  • AML acute myelogenous leukemia
  • B-precursor cell acute lymphoblastic leukemia myelodysplastic leukemia
  • T-cell acute lymphoblastic leukemia T-cell acute lymphoblastic leukemia
  • CML chronic myelogenous leukemia
  • EGFR associated cancers are cancers in which inappropriate EGFR activity (e.g., overexpression of EGFR or mutation of EGFR which causes constitutive tyrosine kinase activity) has been implicated as a contributing factor. Inappropriate EGFR activity has been associated with an adverse prognosis in a number of human cancers, such as neuroblastoma, intestine carcinoma such as rectum carcinoma, colon carcinoma, familiary adenomatous polyposis carcinoma and hereditary non- polyposis colorectal cancer, esophageal carcinoma, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tong carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, medullary thyroidea carcinoma, papillary thyroidea carcinoma, renal carcinoma, kidney parenchym carcinoma, ovarian carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, pancreatic carcinoma, prostate carcinoma, testis carcinoma, breast carcinoma, urinar
  • EGFR appears to have an important role in the development of human brain tumors.
  • a high incidence of overexpression, amplification, deletion and structural rearrangement of the gene coding for EGFR has been found in biopsies of brain tumors.
  • the amplification of the EGFR gene in glioblastoma multiforme tumors is one of the most consistent genetic alterations known, with EGFR being overexpressed in approximately 40% of malignant gliomas and EGFRvIII mutation being found in about 50% of all glioblastomas.
  • Non-small cell lung cancer includes squamous cell carcinomas, adenocarcinoma, bronchioloalveolar carcinoma (BAC), and large cell undifferentiated carcinoma.
  • NSCLC non-small cell lung cancer
  • BAC bronchioloalveolar carcinoma
  • a subset of patients with NSCLC have been shown to have mutations in the tyrosine kinase domain of EGFR which is thought to be necessary for the maintenance of the disease. Treatment of this subset of patients with NSCLC with gefitinib, a tyrosine kinase inhibitor which targets EGFR, has shown rapid and dramatic clinical response.
  • the prophylactic or therapeutic agents of the combination therapies of the invention can be administered sequentially or concurrently.
  • the combination therapies of the invention comprise one or more compounds and at least one other therapy (e.g. , another prophylactic or therapeutic agent) which has the same mechanism of action as said compounds.
  • the combination therapies of the invention comprise one o ⁇ more compounds of the invention and at least one other therapy (e.g., another prophylactic or therapeutic agent) which has a different mechanism of action than said compounds.
  • the combination therapies of the present invention improve the prophylactic or therapeutic effect of one or more compounds of the invention by functioning together with the compounds to have an additive or synergistic effect.
  • the combination therapies of the present invention reduce the side effects associated with the therapies (e.g. , prophylactic or therapeutic agents).
  • the combination therapies of the present invention reduce the effective dosage of one or more of the therapies.
  • the prophylactic or therapeutic agents of the combination therapies can be administered to a subject, preferably a human subject, in the same pharmaceutical composition.
  • the prophylactic or therapeutic agents of the combination therapies can be administered concurrently to a subject in separate pharmaceutical compositions.
  • the prophylactic or therapeutic agents may be administered to a subject by the same or different routes of administration.
  • a pharmaceutical composition comprising one or more compounds of the invention is administered to a subject, preferably a human, to prevent, treat, manage, or ameliorate a proliferative disorder, such as cancer, or one or more symptom thereof.
  • compositions of the invention may also comprise one or more other agents (e.g., prophylactic or therapeutic agents which are currently being used, have been used, or are known to be useful in the prevention, treatment or amelioration of a proliferative disorder or a symptom thereof).
  • agents e.g., prophylactic or therapeutic agents which are currently being used, have been used, or are known to be useful in the prevention, treatment or amelioration of a proliferative disorder or a symptom thereof).
  • the invention provides methods for preventing, managing, treating or ameliorating a proliferative disorder, such as cancer, or one or more symptoms thereof in a subject refractory (either completely or partially) to existing agent therapies for such a proliferative disorder, said methods comprising administering to said subject a dose of an effective amount of one or more compounds of the invention and a dose of an effective amount of one or more therapies (e.g., one or more prophylactic or therapeutic agents useful for the prevention, treatment, management, or amelioration of a proliferative disorder or a symptom thereof).
  • a proliferative disorder such as cancer
  • a subject refractory either completely or partially
  • therapies e.g., one or more prophylactic or therapeutic agents useful for the prevention, treatment, management, or amelioration of a proliferative disorder or a symptom thereof.
  • the invention also provides methods for preventing, treating, managing, or ameliorating a proliferative disorder or a symptom thereof by administering one or more compounds of the invention in combination with any other therapy(ies) to patients who have proven refractory to other therapies but are no longer on these therapies.
  • the compounds of the invention and/or other therapies can be administered to a subject by any route known to one of skill in the art. Examples of routes of administration include, but are not limited to, parenteral, e.g. , intravenous, intradermal, subcutaneous, oral (e.g., inhalation), intranasal, transdermal (topical), transmucosal, and rectal administration.
  • the compounds of the invention can be particularly effective at treating subjects whose cancer has become multi-drug resistant.
  • chemotherapeutic agents initially cause tumor regression, most agents that are currently used to treat cancer target only one pathway to tumor progression. Therefore, in many instances, after treatment with one or more chemotherapeutic agents, a tumor develops multidrug resistance and no longer responds positively to treatment.
  • One of the advantages of inhibiting Hsp90 activity is that several of its client proteins, which are mostly protein kinases or transcription factors involved in signal transduction, have been shown to be involved in the progression of cancer. Thus, inhibition of Hsp90 provides a method of short circuiting several pathways for tumor progression simultaneously.
  • the compounds of the invention can be administered with agents that are tyrosine kinase inhibitors (e.g., gefitinib or erlotinib which inhibit EGFR tyrosine kinase activity).
  • agents that are tyrosine kinase inhibitors e.g., gefitinib or erlotinib which inhibit EGFR tyrosine kinase activity.
  • the compounds of the invention can be administered to patients whose cancer has become resistant to a tyrosine kinase inhibitor (e.g., gefitinib or erlotinib).
  • the compounds of the invention can be administered either alone or in combination with the tyrosine kinase inhibitor.
  • the compounds of the invention are useful for treating patients with hematological cancers that have become resistant to Imatinib, a chemotherapeutic agent that acts by inhibiting tyrosine kinase activity of Bcr-Abl.
  • a chemotherapeutic agent that acts by inhibiting tyrosine kinase activity of Bcr-Abl.
  • treatment with Imatinib typically will induce remission.
  • the remission is not durable because the Bcr-Abl fusion protein develops mutations in the tyrosine kinase domain that cause it to be resistence to Imatinib.
  • Compounds of the invention act by inhibiting the activity of Hsp90 which disrupt Bcr-Abl/Hsp90 complexes. When Bcr-Abl is not complex to Hsp90 it is rapidly degraded. Therefore, compounds of the invention are effective in treating Imatinib resistant leukemias since they act through a different mechanism than Imatinib.
  • Compounds of the invention can be administered alone or with Imatinib in patients who have a Bcr-Abl associated cancer that is not resistant to Imatinib or to patients whose cancer has become resistant to Imatinib.
  • Anticancer agents that can be co-administered with the compounds of the invention include TaxolTM, also referred to as "paclitaxel", is a well-known anti- cancer drug which acts by enhancing and stabilizing microtubule formation, and analogs of Taxol , such as TaxotereTM.
  • TaxolTM also referred to as "paclitaxel”
  • TaxotereTM analogs of Taxol
  • Other anti-cancer agents that can be employed in combination with the compounds of the invention include Avastin, Adriamycin, Dactinomycin,
  • anti-cancer drugs that can be employed in combination with the compounds of the invention include: 20-epi-l,25 dihydroxyvitamin D3; 5- ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti- dorsalizing morphogenetic protein- 1 ; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid;
  • RII retinamide RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone Bl; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1 ; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1 ; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive
  • Preferred anti-cancer drugs are 5-fluorouracil and leucovorin.
  • Other chemotherapeutic agents that can be employed in combination with the compounds of the invention include but are not limited to alkylating agents, antimetabolites, natural products, or hormones.
  • alkylating agents useful for the treatment or prevention of T-cell malignancies in the methods and compositions of the invention include but are not limited to, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, etc.), or triazenes (decarbazine, etc.).
  • nitrogen mustards e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.
  • alkyl sulfonates e.g., busulfan
  • antimetabolites useful for the treatment or prevention of T-cell malignancies in the methods and compositions of the invention include but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
  • folic acid analog e.g., methotrexate
  • pyrimidine analogs e.g., Cytarabine
  • purine analogs e.g., mercaptopurine, thioguanine, pentostatin
  • Examples of natural products useful for the treatment or prevention of T-cell malignancies in the methods and compositions of the invention include but are not limited to vinca alkaloids (e.g., vinblastin, vincristine), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), or biological response modifiers (e.g., interferon alpha).
  • vinca alkaloids e.g., vinblastin, vincristine
  • epipodophyllotoxins e.g., etoposide
  • antibiotics e.g., daunorubicin, doxorubicin, bleomycin
  • enzymes e.g., L-asparaginase
  • biological response modifiers e.g., interferon alpha
  • alkylating agents examples include but are not limited to, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, melphalan, etc.), ethyl enimine and methylmel amines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin, etc.), or triazenes (decarbazine, etc.).
  • nitrogen mustards e.g., mechloroethamine, cyclophosphamide, chlorambucil, melphalan, etc.
  • ethyl enimine and methylmel amines e.g., hexamethlymelamine, thiotepa
  • antimetabolites useful for the treatment or prevention of cancer in the methods and compositions of the invention include but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxouridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
  • folic acid analog e.g., methotrexate
  • pyrimidine analogs e.g., fluorouracil, floxouridine, Cytarabine
  • purine analogs e.g., mercaptopurine, thioguanine, pentostatin
  • natural products useful for the treatment or prevention of cancer in the methods and compositions of the invention include but are not limited to vinca alkaloids (e.g.
  • antibiotics e.g., actinomycin D, daunorubicin, doxorubicin, bleomycin, plicamycin, mitomycin
  • enzymes e.g. , L-asparaginase
  • biological response modifiers e.g., interferon alpha
  • hormones and antagonists useful for the treatment or prevention of cancer in the methods and compositions of the invention include but are not limited to adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g. , diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), gonadotropin releasing hormone analog (e.g., leuprolide).
  • adrenocorticosteroids e.g., prednisone
  • progestins e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate
  • platinum coordination complexes e.g., cisplatin, carboblatin
  • anthracenedione e.g., mitoxantrone
  • substituted urea e.g., hydroxyurea
  • methyl hydrazine derivative e.g., procarbazine
  • adrenocortical suppressant e.g., mitotane, aminoglutethimide
  • anti-cancer agents which act by arresting cells in the G2-M phases due to stabilization or inhibition of microtubules and which can be used in combination with the compounds of the invention include without limitation the following marketed drugs and drugs in development: Erbulozole (also known as R- 55104), Dolastatin 10 (also known as DLS-10 and NSC-376128), Mivobulin isethionate (also known as CI-980), Vincristine, NSC-639829, Discodermolide (also known as NVP-XX-A-296), ABT-751 (Abbott, also known as E-7010), Altorhyrtins (such as Altorhyrtin A and Altorhyrtin C), Spongistatins (such as Spongistatin 1 , Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemado
  • anti -viral agents that can be co-administered with the compounds of the invention include, but are not limited to, Emtricitabine (FTC); Lamivudine (3TC); Carbovir; Acyclovir; Interferon; Famciclovir; Penciclovir; Zidovudine (AZT); Didanosine (ddl); Zalcitabine (ddC); Stavudine (d4T); Tenofovir DF (Viread); Abacavir (ABC); L-(-)-FMAU; L-DDA phosphate prodrugs; ⁇ -D- dioxolane nucleosides such as ⁇ -D-dioxolanyl-guanine (DG), ⁇ -D-dioxolanyl-2,6- diaminopurine (DAPD), and ⁇ -D-dioxolanyl-6-chloropurine (ACP); non-nucleoside RT inhibitors such as
  • anti-parasitic agents that can be co-administered with the compounds of the invention include, but are not limited to, avermectins, milbemycins, lufenuron, imidacloprid, organophosphates, pyrethroids, sufanamides, iodquinol, diloxanide furoate, metronidazole, paromycin, azithromycin, quinacrine, furazolidone, tinidazole, ornidazole, bovine, colostrum, bovine dialyzable leukocyte extract, chloroquine, chloroquine phosphate, diclazuril, eflornithine, paromomycin, pentamidine, pyrimethamine, spiramycin, trimethoprim-sulfamethoxazole, albendazole, quinine, quinidine, tetracycline, pyrimethamine-sulfadoxine, mefl
  • the other therapeutic agent may be a steroid or a non-steroidal antiinflammatory agent.
  • Particularly useful non-steroidal anti-inflammatory agents include, but are not limited to, aspirin, ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic
  • the other therapeutic agent may be an anthihistamine.
  • Useful antihistamines include, but are not limited to, loratadine, cetirizine, fexofenadine, desloratadine, diphenhydramine, chlorpheniramine, chlorcyclizine, pyrilamine, promethazine, terfenadine, doxepin, carbinoxamine, clemastine, tripelennamine, brompheniramine, hydroxyzine, cyclizine, meclizine, cyproheptadine, phenindamine, acrivastine, azelastine, levocabastine, and mixtures thereof.
  • Immunosuppressive agents include glucocorticoids, corticosteroids (such as
  • T cell blockers such as cyclosporin A and FK506
  • purine analogs such as azathioprine (Imuran)
  • pyrimidine analogs such as cytosine arabinoside
  • alkylating agents such as nitrogen mustard, phenylalanine mustard, buslfan, and cyclophosphamide
  • folic acid antagonsists such as aminopterin and methotrexate
  • antibiotics such as rapamycin, actinomycin D, mitomycin C, puramycin, and chloramphenicol
  • human IgG antilymphocyte globulin (ALG)
  • antibodies such as anti-CD3 (OKT3), anti-CD4 (OKT4), anti-CD5, anti-CD7, anti- IL-2 receptor, anti-alpha/beta TCR, anti-ICAM-1, anti-CD20 (Rituxan), anti-IL-12 and antibodies to immuno toxins).
  • E. Compositions such as cyclosporin A and
  • a composition comprises one or more compounds of the invention, or a pharmaceutically acceptable salt, solvate, clathrate, hydrate or prodrug thereof.
  • a composition of the invention comprises one or more prophylactic or therapeutic agents other than a compound of the invention, or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, prodrug thereof.
  • a composition of the invention comprises one or more compounds of the invention, or a pharmaceutically acceptable salt, solvate, clathrate, hydrate or prodrug thereof, and one or more other prophylactic or therapeutic agents.
  • the composition comprises a compound of the invention, or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, or prodrug thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
  • the pharmaceutical compositions can be used in therapy, e.g., to treat a mammal with an infection.
  • the pharmaceutical composition includes one or more additional therapeutic agents, such as one or more additional anti-infective agents.
  • the present invention is the use of a compound of anyone of the formulas disclosed herein for the manufacture of a medicament for treating a mammal with an infection.
  • a pharmaceutical composition comprising a compound represented by any one of the formulas disclosed herein and a pharmaceutically acceptable carrier.
  • the pharmaceutical compositions can be used in therapy, e.g., to treat a mammal with an inflammatory or immune disorder.
  • the pharmaceutical composition includes one or more additional therapeutic agent, such as one or more additional antiinflammatory agent or one or more immunosuppressant.
  • the present invention is the use of a compound of anyone of the formulas disclosed herein for the manufacture of a medicament for treating a mammal with an inflammatory or autoimmune disorder or for treatment of a mammal in need of immunosuppression.
  • a composition of the invention is a pharmaceutical composition or a single unit dosage form.
  • Pharmaceutical compositions and dosage forms of the invention comprise one or more active ingredients in relative amounts and formulated in such a way that a given pharmaceutical composition or dosage form can be used to treat or prevent proliferative disorders, such as cancer.
  • Preferred pharmaceutical compositions and dosage forms comprise a compound of formula (I) - (XXXVI) or a pharmaceutically acceptable prodrug, salt, solvate, clathrate, hydrate, or prodrug thereof, optionally in combination with one or more additional active agents.
  • a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
  • routes of administration include, but are not limited to, parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g. , inhalation), intranasal, transdermal (topical), transmucosal, and rectal administration.
  • parenteral e.g., intravenous, intradermal, subcutaneous, oral (e.g. , inhalation), intranasal, transdermal (topical), transmucosal, and rectal administration.
  • the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous, subcutaneous, intramuscular, oral, intranasal or topical administration to human beings.
  • a pharmaceutical composition is formulated in accordance with routine procedures for subcutaneous administration to human beings.
  • Single unit dosage forms of the invention are suitable for oral, mucosal (e.g., nasal, sublingual, vaginal, buccal, or rectal), parenteral (e.g., subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial), or transdermal administration to a patient.
  • mucosal e.g., nasal, sublingual, vaginal, buccal, or rectal
  • parenteral e.g., subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial
  • transdermal administration to a patient.
  • dosage forms include, but are not limited to: tablets; caplets; capsules, such as soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; ointments; cataplasms (poultices); pastes; powders; dressings; creams; plasters; solutions; patches; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (e.g.
  • aqueous or non-aqueous liquid suspensions oil-in-water emulsions, or a water-in-oil liquid emulsions
  • solutions and elixirs
  • liquid dosage forms suitable for parenteral administration to a patient e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or a water-in-oil liquid emulsions), solutions, and elixirs
  • liquid dosage forms suitable for parenteral administration to a patient sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient.
  • sterile solids e.g., crystalline or amorphous solids
  • compositions, shape, and type of dosage forms of the invention will typically vary depending on their use.
  • a dosage form suitable for mucosal administration may contain a smaller amount of active ingredient(s) than an oral dosage form used to treat the same indication.
  • This aspect of the invention will be readily apparent to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences (1990) 18th ed., Mack Publishing, Easton PA.
  • Typical pharmaceutical compositions and dosage forms comprise one or more excipients. Suitable excipients are well known to those skilled in the art of pharmacy, and non-limiting examples of suitable excipients are provided herein.
  • a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art including, but not limited to, the way in which the dosage form will be administered to a patient.
  • oral dosage forms such as tablets may contain excipients not suited for use in parenteral dosage forms.
  • the suitability of a particular excipient may also depend on the specific active ingredients in the dosage form. For example, the decomposition of some active ingredients can be accelerated by some excipients such as lactose, or when exposed to water. Active ingredients that comprise primary or secondary amines (e.g., N-desmethylvenlafaxine and N,N-didesmethylvenlafaxine) are particularly susceptible to such accelerated decomposition.
  • lactose-free compositions of the invention can comprise excipients that are well known in the art and are listed, for example, in the U.S. Pharmocopia (USP) SP (XXI)/NF (XVI).
  • USP U.S. Pharmocopia
  • lactose-free compositions comprise active ingredients, a binder/filler, and a lubricant in pharmaceutically compatible and pharmaceutically acceptable amounts.
  • Preferred lactose-free dosage forms comprise active ingredients, microcrystalline cellulose, pre-gelatinized starch, and magnesium stearate.
  • This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising active ingredients, since water can facilitate the degradation of some compounds.
  • water e.g., 5%
  • water is widely accepted in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. See, e.g., Jens T. Carstensen (1995) Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, NY, 379-80.
  • water and heat accelerate the decomposition of some compounds.
  • the effect of water on a formulation can be of great significance since moisture and/or humidity are commonly encountered during manufacture, handling, packaging, storage, shipment, and use of formulations.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
  • Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprises a primary or secondary amine are preferably anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.
  • anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are preferably packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
  • compositions and dosage forms that comprise one or more compounds that reduce the rate by which an active ingredient will decompose.
  • compounds which are referred to herein as "stabilizer” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers.
  • compositions of the invention that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to, tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored syrups).
  • dosage forms contain predetermined amounts of active ingredients, and may be prepared by methods of pharmacy well known to those skilled in the art. See generally, Remington's Pharmaceutical Sciences (1990) 18th ed., Mack Publishing, Easton PA.
  • Typical oral dosage forms of the invention are prepared by combining the active ingredient(s) in an admixture with at least one excipient according to conventional pharmaceutical compounding techniques. Excipients can take a wide variety of forms depending on the form of preparation desired for administration.
  • excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents.
  • excipients suitable for use in solid oral dosage forms include, but are not limited to, starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents.
  • tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid excipients are employed. If desired, tablets can be coated by standard aqueous or nonaqueous techniques. Such dosage forms can be prepared by any of the methods of pharmacy. In general, pharmaceutical compositions and dosage forms are prepared by uniformly and intimately admixing the active ingredients with liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation if necessary.
  • a tablet can be prepared by compression or molding.
  • Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free- flowing form such as powder or granules, optionally mixed with an excipient.
  • Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • excipients that can be used in oral dosage forms of the invention include, but are not limited to, binders, fillers, disintegrants, and lubricants.
  • Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, (e.g., Nos. 2208, 2906, 2910), microcrystalline cellulose, and mixtures thereof.
  • Suitable forms of microcrystalline cellulose include, but are not limited to, the materials sold as AVICEL-PH- 101, AVICEL-PH-103 AVICEL RC-581, AVICEL-PH- 105 (available from FMC Corporation, American Viscose Division, Avicel Sales, Marcus Hook, PA), and mixtures thereof.
  • One specific binder is a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose sold as AVICEL RC-581.
  • Suitable anhydrous or low moisture excipients or additives include AVICEL-PH- 103 J and Starch 1500 LM.
  • fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate ( ⁇ g-, granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
  • the binder or filler in pharmaceutical compositions of the invention is typically present in from about 50 to about 99 weight percent of the pharmaceutical composition or dosage form.
  • Disintegrants are used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Tablets that contain too much disintegrant may disintegrate in storage, while those that contain too little may not disintegrate at a desired rate or under the desired conditions. Thus, a sufficient amount of disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredients should be used to form solid oral dosage forms of the invention.
  • the amount of disintegrant used varies based upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
  • Typical pharmaceutical compositions comprise from about 0.5 to about 15 weight percent of disintegrant, preferably from about 1 to about 5 weight percent of disintegrant.
  • Disintegrants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums, and mixtures thereof.
  • Lubricants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil ⁇ e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, and mixtures thereof.
  • Additional lubricants include, for example, a syloid silica gel
  • AEROSIL 200 manufactured by W.R. Grace Co. of Baltimore, MD
  • a coagulated aerosol of synthetic silica marketed by Degussa Co. of Piano, TX
  • CAB-O-SIL a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, MA
  • lubricants are typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated.
  • Active ingredients of the invention can be administered by controlled release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548, 5,073,543, 5,639,476, 5,354,556, and 5,733,566, each of which is incorporated herein by reference.
  • Such dosage forms can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions.
  • Suitable controlled-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the active ingredients of the invention.
  • the invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled-release.
  • controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts.
  • the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time.
  • Advantages of controlled- release formulations include extended activity of the drug, reduced dosage frequency, and increased patient compliance.
  • Controlled-release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time.
  • the drug In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body.
  • Controlled-release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, temperature, enzymes, water, or other physiological conditions or compounds.
  • a particular extended release formulation of this invention comprises a therapeutically or prophylactically effective amount of a compound of formula (I) - (XXXVI), or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, in spheroids which further comprise microcrystalline cellulose and, optionally, hydroxypropylmethyl-cellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
  • spheroids which further comprise microcrystalline cellulose and, optionally, hydroxypropylmethyl-cellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
  • a specific controlled-release formulation of this invention comprises from about 6% to about 40% a compound of formula (I) - (XXXVI), or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, by weight, about 50% to about 94% microcrystalline cellulose, NF, by weight, and optionally from about 0.25% to about 1% by weight of hydroxypropylmethylcellulose, USP, wherein the spheroids are coated with a film coating composition comprised of ethyl cellulose and hydroxypropylmethylcellulose.
  • Parenteral dosage forms can be administered to patients by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial. Because their administration typically bypasses patients' natural defenses against contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
  • Suitable vehicles that can be used to provide parenteral dosage forms of the invention are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • water for Injection USP Water for Injection USP
  • aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride
  • Transdermal, topical, and mucosal dosage forms of the invention include, but are not limited to, ophthalmic solutions, sprays, aerosols, creams, lotions, ointments, gels, solutions, emulsions, suspensions, or other forms known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences (1980 & 1990) 16th and 18th eds., Mack Publishing, Easton PA and Introduction to Pharmaceutical Dosage Forms (1985) 4th ed., Lea & Febiger, Philadelphia. Dosage forms suitable for treating mucosal tissues within the oral cavity can be formulated as mouthwashes or as oral gels. Further, transdermal dosage forms include "reservoir type" or "matrix type” patches, which can be applied to the skin and worn for a specific period of time to permit the penetration of a desired amount of active ingredients.
  • Suitable excipients e.g., carriers and diluents
  • other materials that can be used to provide transdermal, topical, and mucosal dosage forms encompassed by this invention are well known to those skilled in the pharmaceutical arts, and depend on the particular tissue to which a given pharmaceutical composition or dosage form will be applied.
  • excipients include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1,3- diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof to form lotions, tinctures, creams, emulsions, gels or ointments, which are non-toxic and pharmaceutically acceptable.
  • Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well known in the art. See, e.g. , Remington's Pharmaceutical Sciences (1980 & 1990) 16th and 18th eds., Mack Publishing, Easton PA.
  • penetration enhancers can be used to assist in delivering the active ingredients to the tissue.
  • Suitable penetration enhancers include, but are not limited to: acetone; various alcohols such as ethanol, oleyl, and tetrahydrofuryl; alkyl sulfoxides such as dimethyl sulfoxide; dimethyl acetamide; dimethyl formamide; polyethylene glycol; pyrrolidones such as polyvinylpyrrolidone; Kollidon grades (Povidone, Polyvidone); urea; and various water-soluble or insoluble sugar esters such as Tween 80 (polysorbate 80) and Span 60 (sorbitan monostearate).
  • the pH of a pharmaceutical composition or dosage form, or of the tissue to which the pharmaceutical composition or dosage form is applied may also be adjusted to improve delivery of one or more active ingredients.
  • the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery.
  • Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or more active ingredients so as to improve delivery.
  • stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent.
  • Different salts, hydrates or solvates of the active ingredients can be used to further adjust the properties of the resulting composition.
  • the amount of the compound or composition of the invention which will be effective in the prevention, treatment, management, or amelioration of a proliferative disorders, such as cancer, or one or more symptoms thereof, will vary with the nature and severity of the disease or condition, and the route by which the active ingredient is administered.
  • the frequency and dosage will also vary according to factors specific for each patient depending on the specific therapy (e.g., therapeutic or prophylactic agents) administered, the severity of the disorder, disease, or condition, the route of administration, as well as age, body, weight, response, and the past medical history of the patient.
  • Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • Suitable regiments can be selected by one skilled in the art by considering such factors and by following, for example, dosages reported in the literature and recommended in the Physician 's Desk Reference (57th ed., 2003).
  • Exemplary doses of a small molecule include milligram or microgram amounts of the small molecule per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram).
  • the recommended daily dose range of a compound of the invention for the conditions described herein lie within the range of from about 0.01 mg to about 1000 mg per day, given as a single once-a-day dose preferably as divided doses throughout a day.
  • the daily dose is administered twice daily in equally divided doses.
  • a daily dose range should be from about 5 mg to about 500 mg per day, more specifically, between about 10 mg and about 200 mg per day.
  • the therapy should be initiated at a lower dose, perhaps about 1 mg to about 25 mg, and increased if necessary up to about 200 mg to about 1000 mg per day as either a single dose or divided doses, depending on the patient's global response.
  • dosages of the active ingredient may be necessary to use dosages of the active ingredient outside the ranges disclosed herein in some cases, as will be apparent to those of ordinary skill in the art.
  • clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with individual patient response. Different therapeutically effective amounts may be applicable for different proliferative disorders, as will be readily known by those of ordinary skill in the art. Similarly, amounts sufficient to prevent, manage, treat or ameliorate such proliferative disorders, but insufficient to cause, or sufficient to reduce, adverse effects associated with the compounds of the invention are also encompassed by the above described dosage amounts and dose frequency schedules. Further, when a patient is administered multiple dosages of a compound of the invention, not all of the dosages need be the same. For example, the dosage administered to the patient may be increased to improve the prophylactic or therapeutic effect of the compound or it may be decreased to reduce one or more side effects that a particular patient is experiencing.
  • the dosage of the composition of the invention or a compound of the invention administered to prevent, treat, manage, or ameliorate a proliferative disorders, such as cancer, or one or more symptoms thereof in a patient is 150 ⁇ g/kg, preferably 250 ⁇ g/kg, 500 ⁇ g/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg, 25 mg/kg, 50 mg/kg, 75 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, or 200 mg/kg or more of a patient's body weight.
  • the dosage of the composition of the invention or a compound of the invention administered to prevent, treat, manage, or ameliorate a proliferative disorders, such as cancer, or one or more symptoms thereof in a patient is a unit dose of 0.1 mg to 20 mg, 0.1 mg to 15 mg, 0.1 mg to 12 mg, 0.1 mg to 10 mg, 0.1 mg to 8 mg, 0.1 mg to 7 mg, 0.1 mg to 5 mg, 0.1 to 2.5 mg, 0.25 mg to 20 mg, 0.25 to 15 mg, 0.25 to 12 mg, 0.25 to 10 mg, 0.25 to 8 mg, 0.25 mg to 7m g, 0.25 mg to 5 mg, 0.5 mg to 2.5 mg, 1 mg to 20 mg, 1 mg to 15 mg, 1 mg to 12 mg, 1 mg to 10 mg, 1 mg to 8 mg, 1 mg to 7 mg, 1 mg to 5 mg, or 1 mg to 2.5 mg.
  • the dosages of prophylactic or therapeutic agents other than compounds of the invention, which have been or are currently being used to prevent, treat, manage, or disease or disorder, e.g. a proliferative disorders, such as cancer, or one or more symptoms thereof can be used in the combination therapies of the invention.
  • dosages lower than those which have been or are currently being used to prevent, treat, manage, or ameliorate a disease or disorder, e.g. a proliferative disorders, or one or more symptoms thereof are used in the combination therapies of the invention.
  • the recommended dosages of agents currently used for the prevention, treatment, management, or amelioration of a disease or disorder e.g.
  • a proliferative disorders such as cancer, or one or more symptoms thereof, can obtained from any reference in the art including, but not limited to, Hardman et al. , eds., 1996, Goodman & Gilman's The Pharmacological Basis Of Basis Of Therapeutics 9 th Ed, Mc-Graw-Hill, New York; Physician's Desk Reference (PDR) 57 th Ed., 2003, Medical Economics Co., Inc., Montvale, NJ, which are incorporated herein by reference in its entirety.
  • the therapies are administered less than 5 minutes apart, less than 30 minutes apart, 1 hour apart, at about 1 hour apart, at about 1 to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, at about 12 hours to 18 hours apart, 18 hours to 24 hours apart, 24 hours to 36 hours apart, 36 hours to 48 hours apart, 48 hours to 52 hours apart, 52 hours to 60 hours apart, 60 hours to 72 hours apart, 72 hours to 84 hours apart, 84 hours to 96 hours apart, or 96 hours to 120 hours part.
  • two or more therapies e.
  • one or more compounds of the invention and one or more other the therapies are cyclically administered. Cycling therapy involves the administration of a first therapy (e.g., a first prophylactic or therapeutic agents) for a period of time, followed by the administration of a second therapy (e.g., a second prophylactic or therapeutic agents) for a period of time, followed by the administration of a third therapy (e.g., a third prophylactic or therapeutic agents) for a period of time and so forth, and repeating this sequential administration, i.e., the cycle in order to reduce the development of resistance to one of the agents, to avoid or reduce the side effects of one of the agents, and/or to improve the efficacy of the treatment.
  • a first therapy e.g., a first prophylactic or therapeutic agents
  • a second therapy e.g., a second prophylactic or therapeutic agents
  • a third therapy e.g., a third prophylactic or therapeutic agents
  • administration of the same compound of the invention may be repeated and the administrations may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or 6 months.
  • administration of the same prophylactic or therapeutic agent may be repeated and the administration may be separated by at least at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or 6 months.
  • the invention provides a method of preventing, treating, managing, or ameliorating a proliferative disorders, such as cancer, or one or more symptoms thereof, said methods comprising administering to a subject in need thereof a dose of at least 150 ⁇ g/kg, preferably at least 250 ⁇ g/kg, at least 500 ⁇ g/kg, at least 1 mg/kg, at least 5 mg/kg, at least 10 mg/kg, at least 25 mg/kg, at least 50 mg/kg, at least 75 mg/kg, at least 100 mg/kg, at least 125 mg/kg, at least 150 mg/kg, or at least 200 mg/kg or more of one or more compounds of the invention once every day, preferably, once every 2 days, once every 3 days, once every 4 days, once every 5 days, once every 6 days, once every 7 days, once every 8 days, once every 10 days, once every two weeks, once every three weeks, or once a month.
  • a dose of at least 150 ⁇ g/kg preferably at least 250 ⁇ g/kg, at least 500
  • the compounds of the invention may be used as research tools (for example, to evaluate the mechanism of action of new drug agents, to isolate new drug discovery targets using affinity chromatography, as antigens in an ELISA or ELISA- like assay, or as standards in in vitro or in vivo assays).
  • Example 1 4- ⁇ 5-Hydroxy-4-[4-methoxy-3-(methylpropylamino)phenyl]-4H- [l,2,4]triazol-3-yl ⁇ -6-isopropyl-benzene-l,3-diol
  • N-(2-Methoxy-5-nitro-phenyl)-N-methyl-propionamide (3) (10. Og 42mmol ) and borane-methyl sulfide complex (21 mL of 2.0M solution in tetrahydrofurane) in 50 mL THF were heated under reflux for 30 min, cooled and quenched by ice- water (slowly). Extraction with EtOAc and the organic layer washed with brine dried (Na 2 SO 4 ), filtered and evaporated in vacuo to give (9.1g, 96% ) (2-Methoxy-5-nitro- phenyl)-methyl-propyl-amine (4) as a yellow oil.
  • Example 3 4-(4- ⁇ 3-[(2-Dimethylamino-ethyl)-methyl-amino]-4-methoxy-phenyl ⁇ - 5-mercapto-4H-[ 1 ,2,4]triazol-3-yl)-6-isopropyl-benzene-l ,3-diol
  • the white precipitate thus obtained was filtered, washed with water (3 X 20 mL) and dried.
  • the crude product was then re-dissolved in a mixture of 20 mL of ethyl acetate, dried over anhydrous Na 2 SO 4 and passed through a short pad of silica gel with an additional 15 mL of ethyl acetate as eluent.
  • Example 5 4- ⁇ 4-[3-(Cyclopropylmethylmethylamino)-4-methoxy-phenyl]-5- mercapto-4H-[l,2,4]triazol-3-yl ⁇ -6-isopropylbenzene-l,3-diol
  • Example 7 N-Ethyl-N- ⁇ 5-[3-(5-ethyl-2,4-dihydroxy-phenyl)-5-mercapto- [l,2,4]triazol-4-yl]-2-methoxy-phenyl ⁇ -acetamide, ESMS clcd for Q n H 24 N 4 O 4 S: 428.15; Found: 429.2 (M+H) + .
  • Example 8 4-[4-(3-Diethylamino-4-methoxy-phenyl)-5-mercapto-4H-[ 1 ,2,4]triazol-
  • Example 10 4-[4-(4-Diethylamino-phenvlV5-mercamo-4H-ri,2.41triazol-3-vll-6- ethyl -benzene- 1 ,3-diol ESMS clcd for C 20 H 24 N 4 O 2 S: 384.16; Found: 385.2 (M+H) + .
  • EjcamElei2 4-Ethyl-6-[4-(4-imidazol-l-yl-phenyl)-5-mercapto-4H-[l,2,4]triazol-3- yl]-benzene-l ,3-diol ESMS clcd for Ci 9 H n N 5 O 2 S: 379.11 ; Found: 380.2 (M+H) + .
  • Example 13 4-[4-(2,5-Diethoxy-4-morpholin-4-yl-phenyl)-5-mercapto-4H- [l,2,4]triazol-3-yl]-6-ethyl-benzene-l,3-diol ESMS clcd for C 24 H 30 N 4 O 5 S: 486.19; Found: 487.3 (M+H) + .
  • Example 14 4-Ethyl-6- ⁇ 4-[3-(isopropyl-propyl-amino)-4-methoxy-phenyl]-5- mercapto-4H-[l,2,4]triazol-3-yl ⁇ -benzene-l,3-diol
  • Example 15 4-[4-(4-Dimethylamino-3-methoxy-phenyl)-5-mercapto-4H- [l,2,4]triazol-3-yl]-6-ethyl-benzene-l,3-diol ESMS clcd for Ci 9 H 22 N 4 O 3 S: 386.14; Found: 387.2 (M+H) + .
  • Example 17 4-[4-(3-Dimethylamino-phenyl)-5-mercapto-4H-[l,2,4]triazol-3-yl]-6- ethyl-benzene- 1 , 3 -diol ESMS clcd for Ci 8 H 20 N 4 O 2 S: 356.13; Found: 357.2 (M+H) + .
  • Example 18 4-Ethyl-6- ⁇ 4-[3-(isopropyl-methyl-amino)-4-methoxy-phenyl]-5- mercapto-4H-[l ,2,4]triazol-3-yl ⁇ -benzene-l ,3-diol ESMS clcd for C 21 H 26 N 4 O 3 S: 414.17; Found: 415.2 (M+H) + .
  • Example 21 4-Isopropyl-6- ⁇ 4-[3-(isopropyl-propyl-amino)-4-methoxy-phenyl]-5- mercapto-4H-[l,2,4]triazol-3-yl ⁇ -benzene-l,3-diol ESMS clcd for C 24 H 32 N 4 O 3 S: 456.22; Found: 457.3 (M+H) + .
  • Example 22 4-Ethyl-6- ⁇ 4-[3-(ethyl-isopropyl-amino)-4-methoxy-phenyl]-5- mercapto-4H- [ 1 ,2,4]triazol-3 -yl ⁇ -benzene- 1 ,3 -diol
  • Example 24 4-Isopropyl-6- ⁇ 5-mercapto-4-[4-methoxy-3-(methyl-propyl-amino)- phenyl]-4H-[l,2,4]triazol-3-yl ⁇ -benzene-l,3-diol
  • Example 25 4- ⁇ 4-[3-(Ethyl-methyl-amino)-4-methoxy-phenyl]-5-mercapto-4H- [ 1 ,2,4]triazol-3 -yl ⁇ -6-isopropyl -benzene- 1 ,3 -diol
  • Example 26 4-Isopropyl-6-(5-mercapto-4- ⁇ 4-methoxy-3-[methyl-(3-methyl-butyl)- amino] -phenyl ⁇ -4H-[ 1 ,2,4]triazol-3 -yl)-benzene- 1 ,3 -diol ESMS clcd for C 24 H 32 N 4 O 3 S: 456.22; Found: 457.2 (M+H) + .
  • Example 27 4-Isopropyl-6- ⁇ 5-mercapto-4-[4-methoxy-3 -(methyl -propyl-amino)- phenyl]-4H-[l,2,4]triazol-3-yl ⁇ -benzene-l,3-diol; compound with hydrogen chloride ESMS clcd for C 22 H 29 ClN 4 O 3 S: 464.16; Found: 429.3 (M+H) + .
  • Example 28 4- ⁇ 4-[3-(Butyl-methyl-amino)-4-methoxy-phenyl]-5-mercapto-4H- [l,2,4]triazol-3-yl ⁇ -6-isopropyl-benzene-l,3-diol ESMS clcd for C 23 H 30 N 4 O 3 S: 442.20; Found: 443.3 (M+H) + .
  • Example 30 4-(4- ⁇ 3-[(2-Imidazol-l-yl-ethyl)-methyl-amino]-4-methoxy-phenyl ⁇ -5- mercapto-4H-[l,2,4]triazol-3-yl)-6-isopropyl-benzene-l,3-diol ESMS clcd for C 24 H 28 N 6 O 3 S: 480.19; Found: 481.1 (M+H) + . 4-(4-(3-(lH-pyrrol-l-yl)phenyl)-5-mercapto-4H-l,2,4-triazol-3-yl)-6- ethylbenzene- 1 ,3 -diol
  • Example 32 4-(4-(4-( 1 H-pyrazol- 1 -yl)phenyl)-5 -mercapto-4H- 1 ,2,4-triazol-3-yl)-6- ethylbenzene- 1 ,3-diol
  • Example 33 4-(4-(3-(dimethylamino)-4-(methylthio)phenyl)-5-mercapto-4H-l ,2,4- triazol-3-yl)-6-isopropylbenzene-l,3-diol ESMS clcd for C 20 H 24 N 4 O 2 S 2 : 416.13; Found: 417.1 (M+H) + .
  • Example 34 4-isopropyl-6-(5-mercapto-4-(4-methoxy-3-(propylamino)phenyl)-4H-
  • Example 35 4-[4-(4-Amino-3-hydroxy-phenyl)-5-mercapto-4H-[l ,2,4]triazol-3-yl]- 6-ethyl -benzene- 1 ,3-diol ESMS clcd for C 16 H 16 N 4 O 3 S: 344.09; Found: 345.1 (M+H) + .
  • Example 36 4-ethyl-6-(4-(3-hydroxy-4-(methylamino)phenyl)-5-mercapto-4H- l,2,4-triazol-3-yl)benzene-l,3-diol
  • Example 37 4-(4-(3-aminophenyl)-5-mercapto-4H-l ,2,4-triazol-3-yl)-6- ethylbenzene-l,3-diol
  • Example 38 4-[4-(4-Dimethylamino-3-methyl-phenyl)-5-mercapto-4H- [1 ,2,4]triazol-3-yl]-6-ethyl-benzene-l ,3-diol ESMS clcd for Cj 9 H 23 N 4 O 2 S: 371.1; Found: 371.1 (M + H) + .
  • Example 39 4-[4-(3-Imidazol-l-yl-phenyl)-5-mercapto-4H-[l,2,4]triazol-3-yl]-6- isopropyl-benzene-1 ,3-diol
  • Example 40 2- ⁇ 3-[3-(2,4-Dihydroxy-5-isopropyl-phenyl)-5-mercapto-[l,2,4]triazol- 4-yl]-phenyl ⁇ -5-methyl-2,4-dihydro-pyrazol-3-one
  • Example 42 4-(4-(4-aminophenyl)-5-hydroxy-4H-l ,2,4-triazol-3-yl)-6- isopropylbenzene-1 ,3-diol
  • Example 43 4-(4-(4-(dimethylamino)phenyl)-5-mercapto-4H- 1 ,2,4-triazol-3-yl)-6- isopropylbenzene-1 ,3-diol
  • Example 44 4-isopropyl-6-(5-mercapto-4-(4-(methyl(propyl)amino)phenyl)-4H- 1 ,2,4-triazol-3-yl)benzene-l ,3-diol
  • Example 47 1 -(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-mercapto-4H-l ,2,4- triazol-4-yl)phenyl)urea
  • Example 48 4-(4-(4-(dipropylamino)phenyl)-5-mercapto-4H-l,2,4-triazol-3-yl)-6- isopropylbenzene-1 ,3-diol
  • Example 50 4-(5-hydroxy-4-(4-((2-methoxyethyl)(methyl)amino)phenyl)-4H- 1,2,4- triazol-3-yl)-6-isopropylbenzene-l,3-diol
  • Example 51 4-(4-(4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)phenyl)-5-hydroxy-4H- 1 ,2,4-triazol-3-yl)-6-isopropylbenzene- 1 ,3-diol
  • Example 55 4-(5-hydroxy-4-(4-(4-methylpiperazin-l-yl)phenyl)-4H-l,2,4-triazol-3- yl)-6-isopropylbenzene-l ,3-diol hydrochloride
  • Example 56 4-(5-hydroxy-4-(4-(4-methylpiperidin-l -yl)phenyl)-4H-l ,2,4-triazol-3- yl)-6-isopropylbenzene- 1 ,3-diol
  • Example 57 4-(4-(4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)-5-hydroxy- 4H-l,2,4-triazol-3-yl)-6-isopropylbenzene-l,3-diol
  • Example 58 4-(4-(4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)-5-hydroxy- 4H-1 ,2,4-triazol-3-yl)-6-isopropylbenzene-l ,3-diol dihydrochloride
  • Example 59 4-(4-(4-(dimethylamino)-3-fluorophenyl)-5-hydroxy-4H-l ,2,4-triazol- 3-yl)-6-isopropylbenzene-l,3-diol
  • Example 60 4-(4-(4-(dimethylamino)phenyl)-5-mercapto-4H-l,2,4-triazol-3-yl)-6- isopropylbenzene-1 ,3-diol hydrochloride
  • 1H-NMR (DMSO-d 6 ) ⁇ (ppm):9.6-9.4(b, 2H), 7.0(m, 2H), 6.80(s, IH), 6.62 (m, 2H), 6.23(s, IH), 2.9(m, 7H), 0.95(d, J 6.6 Hz, 6H);
  • Example 62 4-(4-(4-((2-(dimethylamino)ethyl)(methyl)amino)-3-fluorophenyl)-5- hydroxy-4H-l ,2,4-triazol-3-yl)-6-isopropylbenzene-l ,3-diol
  • Example 65 5-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-l,2,4-triazol-4- yl)-2-(dimethylamino)benzenesulfonamide hydrochloride
  • Example 68 2-((5-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-mercapto-4H- 1,2,4- triazol-4-yl)-2-methoxyphenyl)(methyl)amino)acetic acid
  • Example 70 4-(4-(3-((2-hydroxyethyl)(methyl)amino)-4-methoxyphenyl)-5- mercapto-4H-l,2,4-triazol-3-yl)-6-isopropylbenzene-l,3-diol
  • Example 71 4-(4-(3-(dimethylamino)-4-ethylphenyl)-5-mercapto-4H-l,2,4-triazol- 3-yl)-6-isopropylbenzene-l,3-diol
  • Example 74 4-(4-(3-(dipropylamino)phenyl)-5-mercapto-4H- 1 ,2,4-triazol-3-yl)-6- isopropylbenzene- 1 , 3 -diol
  • Example 76 4-(4-(4-ethyl-3-(methyl(propyl)amino)phenyl)-5-mercapto-4H- 1,2,4- triazol-3-yl)-6-isopropylbenzene-l,3-diol
  • Hsp90 protein is obtained from Stressgen (Cat#SPP-770). Assay buffer: 100 mM Tris-HCl, Ph7.4, 20 mM KCl, 6 mM MgCl 2 . Malachite green (0.0812% w/v) (M9636) and polyviny alcohol USP (2.32% w/v) (Pl 097) are obtained from Sigma. A Malachite Green Assay (see Methods MoI Med, 2003, 85:149 for method details) is used for examination of ATPase activity of Hsp90 protein.
  • Hsp90 protein in assay buffer 100 mM Tris-HCl, Ph7.4, 20 mM KCl, 6 mM MgCl 2
  • ATP negative control
  • a positive control a compound of the invention
  • Malachite green reagent is added to the reaction.
  • the mixtures are incubated at 37 0 C for 4 hours and sodium citrate buffer (34% w/v sodium citrate) is added to the reaction.
  • the plate is read by an ELISA reader with an absorbance at 620 nm.
  • Example 78 Degradation of Hsp90 Client Proteins via Inhibition of Hsp9090 Activity
  • BT-474 cells are treated with 0.5 ⁇ M, 2 ⁇ M, or 5 ⁇ M of 17 AAG (a positive control) or 0.5 ⁇ M, 2 ⁇ M, or 5 ⁇ M of a compound of the invention overnight in
  • each cytoplasmic sample is prepared from 1x10 6 cells by incubation of cell lysis buffer (#9803, cell Signaling Technology) on ice for 10 minutes.
  • the resulting supernatant used as the cytosol fractions is dissolved with sample buffer for SDS-PAGE and run on a SDS-PAGE gel, blotted onto a nitrocellulose membrane by using semi-dry transfer.
  • Non-specific binding to nitrocellulose is blocked with 5% skim milk in TBS with 0.5% Tween at room temperature for 1 hour, then probed with anti-Her2/ErB2 mAb (rabbit IgG, #2242, Cell Signaling) and anti-Tubulin (T9026, Sigma) as housekeeping control protein.
  • HRP-conjugated goat anti-rabbit IgG (H+L) and HRP-conjugated horse anti-mouse IgG (H+L) are used as secondary Ab (#7074. #7076, Cell Signaling) and LumiGLO reagent, 2Ox Peroxide (#7003, Cell Signaling) is used for visualization.
  • Her2 an Hsp90 client protein, is expected to be degraded when cells are treated with compounds of the invention.
  • MV-4-11 cells (20,000 cells/well) were cultured in 96- well plates and maintained at 37 0 C for several hours. The cells were treated with a compound of the invention or 17AAG (a positive control) at various concentrations and incubated at 37 0 C for 72 hours. Cell survival was measured with Cell Counting Kit-8 (Dojindo Laboratories, Cat. # CK04).
  • IC 50 range for Her2 degradation by compounds of the invention is lised below in Table 2.
  • Table 2 IC 50 range of compounds of the invention
  • cells are washed twice with lxPBS/l%FBS, and then stained with anti-Her2- FITC (#340553, BD) for 30 min at 4 0 C. Cells are then washed three times in FACS buffer before the fixation in 0.5 ml 1% paraformadehydrede. Data is acquired on a FACSCalibur system. Isotype-matched controls are used to establish the non-specific staining of samples and to set the fluorescent markers. A total 10,000 events are recorded from each sample. Data are analysed by using CellQuest software (BD Biosciences).
  • Leukemia cell line, Kasumi-1 was used for testing c-kit degradation induced by Hsp90 inhibitors of the invention.
  • the cells (3XlO 5 per well) were treated with 17AAG (0.5 ⁇ M) or Compound 11 (0.05 ⁇ M or 0.5 ⁇ M) for about 18 h.
  • the cells were collected and centrifuged (SORVALL RT 6000D) at 1200 rpm for 5 min. The supernatants were discarded, and the cells were washed one time with IX PBS. After centrifugation the cells were stained with FITC conjugated c-kit antibody
  • 17- AAG which is a potent Hsp90 inhibitor and is in phase 2 clinical trials, could not induce c-kit degradation at 0.5 ⁇ M in Kasumi-1 cells (see fig. 1). Since the compounds of the invention cause c-kit degradation more efficiently than other Hsp90 inhibitors, the compounds of the invention are expected to be more effective in the treatment of c-kit associated tumors, such as leukemias, mast cell tumors, small cell lung cancer, testicular cancer, some cancers of the gastrointestinal tract (including GIST), and some central nervous system. The results of the FACS analysis were confirmed with Western blot analysis
  • Hsp90 inhibitors of the invention were seeded in 6-well plates at 5 X 10 5 cells/well. The cells were treated with 17AAG (100 nM or 400 nM), Compound 11(100 nM or 400 nM) or Compound 12 (100 nM or 400 nM), and cell lysis was prepared 24 h after treatment. Equal amount of proteins were used for Western blot analysis. The compounds of the invention potently induced degradation of c-Met in this cell line due to inhibition of Hsp90 (see Fig. 3).
  • cells are washed once with 1 xPBS/1 %FBS, and then stained in binding buffer with FITC-conjugated Annexin V and Propidium iodide (PI) (all obtained from BD Biosciences) for 30 min at 4°C.
  • FITC-conjugated Annexin V and Propidium iodide (PI) all obtained from BD Biosciences
  • PI Propidium iodide
  • Example 80 Necrosis in a nude Mouse Tumor Model
  • the mouse mammary carcinoma cell line, EMT6 (ATCC #CRL-2755), is obtained from the American Type Culture Collection (ATCC; Manassas, Virginia, USA).
  • the cell line is cultured in growth media prepared from 50% Dulbecco's Modified Eagle Medium (high glucose), 50% RPMI Media 1640, 10% fetal bovine serum (FBS), 1% 10OX L-glutamine, 1% 10OX Penicillin-Streptomycin, 1% IOOX sodium pyruvate and 1% IOOX MEM non-essential amino acids.
  • FBS is obtained from ATCC and all other reagents are obtained from Invitrogen Corp. (Carlsbad, California, USA).
  • a 90% confluent flask is washed with 10 ml of room temperature phosphate buffered saline (PBS) and the cells are disassociated by adding 5 ml IX Trypsin-EDTA (Invitrogen) and incubating at 37 0 C until the cells detach from the surface of the flask.
  • PBS room temperature phosphate buffered saline
  • IX Trypsin-EDTA Invitrogen
  • 5 ml of growth media is added and then the contents of the flask are centrifuged to pellet the cells. The supernatant is aspirated and the cell pellet is resuspended in 10 ml of growth media and the cell number determined using a hemocytometer.
  • mice Seven to eight week old, female Crl:CD-l- «wBR (nude) mice are obtained from Charles River Laboratories (Wilmington, Massachusetts, USA). Animals are housed 4-5/cage in micro-isolators, with a 12hr/12hr light/dark cycle, acclimated for at least 1 week prior to use and fed normal laboratory chow ad libitum. Studies are conducted on animals between 8 and 10 weeks of age at implantation. To implant EMT6 tumor cells into nude mice, the cells are trypsinized as above, washed in PBS and resusupended at a concentration of 10 x 10(6) cells/ml in PBS. Using a 27 gauge needle and 1 cc syringe, 0.1 ml of the cell suspension is injected subcutaneously into the flank of each nude mouse.
  • a stock solution of the test article is prepared by dissolving an appropriate amount of the compound in dimethyl sulfoxide (DMSO) by sonication in an ultrasonic water bath.
  • DMSO dimethyl sulfoxide
  • Cremophore RH40 polyoxyl 40 hydrogenated castor oil; BASF Corp., Aktiengesellschaft, Ludwigshafen, Germany
  • DMSO stock solution is diluted 1 :10 with 20% Cremophore RH40.
  • the final DRD formulation for dosing contains 10% DMSO, 18% Cremophore RH40, 3.6% dextrose, 68.4% water and the appropriate amount of test article.
  • Tumor-bearing animals are given a single intravenous (i.v.) bolus injections of either DRD vehicle or a compound of the invention formulated in DRD, both at 1O mL per kg body weight. Then, 4-24 hr after drug treatment, tumors are excised, cut in half and fixed overnight in 10% neutral-buffered formalin. Each tumor is embedded in paraffin with the cut surfaces placed downwards in the block, and rough cut until a complete section is obtained. From each rumor, 5 ⁇ M serial sections are prepared and stained with hematoxylin and eosin. Slides are evaluated manually using light microscopy with a 10 x 10 square gridded reticle. The percentage of necrosis in a tumor is quantified at 200X magnification by scoring the total number of grid squares containing necrosis and the total number of grid squares containing viable tumor cells.
  • the mouse mammary carcinoma cell line, EMT6 (ATCC #CRL-2755), is obtained from the American Type Culture Collection (ATCC; Manassas, Virginia, USA).
  • the cell line is cultured in growth media prepared from 50% Dulbecco's Modified Eagle Medium (high glucose), 50% RPMI Media 1640, 10% fetal bovine serum (FBS), 1% IOOX L-glutamine, 1% IOOX Penicillin-Streptomycin, 1% IOOX sodium pyruvate and 1% IOOX MEM non-essential amino acids.
  • FBS is obtained from ATCC and all other reagents are obtained from Invitrogen Corp. (Carlsbad, California, USA).
  • a 90% confluent flask is washed with 10 mL of room temperature phosphate buffered saline (PBS) and the cells are disassociated by adding 5 mL IX Trypsin-EDTA (Invitrogen) and incubating at 37°C until the cells detach from the surface of the flask.
  • IX Trypsin-EDTA Invitrogen
  • 5 mL of growth media is added and then the contents of the flask are centrifuged to pellet the cells. The supernatant is aspirated and the cell pellet is resuspended in 10 mL of growth media and the cell number determined using a hemocytometer.
  • mice Approximately 1 -3 x 10 6 cells per flask are seeded into 175 cm 2 flasks containing 50 mL of growth media and incubated at 37 0 C in a 5% CO 2 incubator. When the flasks reach 90% confluence, the above passaging process is repeated until sufficient cells have been obtained for implantation into mice. Seven to eight week old, female Crl:CD-l-nwBR (nude) mice are obtained from Charles River Laboratories (Wilmington, Massachusetts, USA). Animals are housed 4-5/cage in micro-isolators, with a 12hr/12hr light/dark cycle, acclimated for at least 1 week prior to use and fed normal laboratory chow ad libitum.
  • EMT6 tumor cells are trypsinized as above, washed in PBS and resusupended at a concentration of 10 x 10 6 cells/mL in PBS.
  • 0.1 mL of the cell suspension is injected subcutaneously into the flank of each nude mouse.
  • tumors are permitted to develop in vivo until the majority reach 40-90 mm 3 in tumor volume (to minimize the extent of tumor necrosis), which typically require 4-6 days following implantation.
  • 125 ⁇ L of a 0.6 N phosphoric acid and 325 ⁇ L acetone are added, and the samples vigorously vortexed and then microcentrifuged at 3000 RPM for 15 min to pellet cell debris.
  • the optical absorbance of 200 ⁇ L of supernatant is then measured at 620 nM in a Triad spectrophotometer (Dynex Technologies, Chantilly, Virginia, USA). Background OD 62O values from similarly sized groups of vehicle or test article- treated animals that have not been injected with dye are subtracted as background. OD 620 values are then normalized for tumor weight and dye uptake is calculated relative to vehicle-treated tumors.
  • Evans Blue dye assay is employed as a measurement of tumor blood volume (Graff et al, Eur J Cancer 36:1433-1440, 2000).
  • Evans Blue dye makes a complex with serum albumin by electrostatic interaction between the sulphonic acid group of the dye and the terminal cationic nitrogens of the lysine residues in albumin. The dye leaves the circulation very slowly, principally by diffusion into extravascular tissues while still bound to albumin.
  • Albumin-dye complex taken up by tumors is located in the extracellular space of non-necrotic tissue, and intracellular uptake and uptake in necrotic regions is negligible.
  • the amount of dye present in a tumor is a measurement of the tumor blood volume and microvessel permeability.
  • Compounds of the invention are expected to result in substantially decreased tumor dye uptake relative to vehicle-treated animals. Such a decrease in dye penetration into the tumor is consistent with there being a loss of blood flow to tumors due to blockage of tumor vasculature, consistent with a vascular disrupting mechanism of action.
  • Example 82 Inhibition of HUVEC cell migration
  • HUVEC human umbilical vein endothelial cell migration assay
  • HUVEC cells passage number 4
  • time-lapse imaging is performed with the live cell imaging system on an inverted microscope supplied with 6-7% CO 2 .
  • the temperature is kept at 37°C. Images are taken every 30 minutes using the 2X objective for up to 106 hr or every 60 seconds using the 2OX objective for 30 min.
  • Confluent HUVEC cultures are scraped similarly to make a blank area, followed by culturing in HUVEC medium for 15 hr without treatment.
  • the migration areas which are imaged as time-lapse sequences for each well, are used as a basis to standardize/correct migration rates. Then, migration of cells under different treatments is imaged at the same time to generate time-lapse image sequences for each well. Time-lapse movies are further analyzed by measuring areas that are covered by migrating cells.
  • HUVEC cells are activated by the presence of VEGF and basic FGF.
  • Compounds of the invention e.g. 100 nM and 1 ⁇ M
  • Example 83 Enhanced VE-cadherin junctions of HUVEC cells
  • HUVEC cells are treated with DMSO or a compound of the invention (e.g. 10, 100 and 100OnM) for 24 hrs and fixed for immunostaining.
  • DMSO concentration is 1 : 100 for all treatments.
  • cells are stained with a mixture of 2 polyclonal anti -human VE-cadherin Abs followed by staining with a mixture of fluorescent secondary antibodies. It is expected that with compounds of the invention, VE-cadherin staining will be extremely strong in cell-cell junction regions, but not the non-contacted regions compared to that in DMSO treated cultures.
  • Compounds of the invention are expected to enhance the assembly of cell- cell junctions of activated human endothelial cells, likely through induction of the accumulation of VE-cadherin molecules at the junctions. This effect could result in limited motility of the cells and reducing permeability of the endothelium, thus contributing to the cell migration inhibition and the potential anti-angiogenesis effect of compounds of the invention.
  • Example 84 Inhibition of the Production of Inflammatory Cytokines in Human PBMCs Human PBMC are isolated using Ficoll 400 and diatrizoate sodium
  • the PBMCs are primed with human IFN- ⁇ (800 U/ml, . Pierce Biotechnology #R- IFNG-50), seeded at 0.5x10 6 /100 ⁇ L/well in 96-well U-bottom plate with culture medium (RPMI 1640, 10% FBS, 1% Pen/Strep), and incubated in 37 0 C for overnight.
  • the cells are then stimulated with l ⁇ g/ml of LPS (Lipopolysaccharide, Sigma#L2654-lMG) or 0.025% of SAC (Staphylococcus Aureus Cowan, Calbiochem-Novabiochem Corp.
  • LPS Lipopolysaccharide
  • SAC Staphylococcus Aureus Cowan, Calbiochem-Novabiochem Corp.
  • Example 85 Suppression of Glucocorticoid Receptor Levels in Rat and Human PBMCs
  • PBMCs Whole blood samples from healthy human volunteers and male SD rats are collected and the PBMCs are isolated immediately as follows. 5 ml of whole blood is diluted with an equal volume of sterile Ix PBS. The diluted blood is overlayed carefully into a sterile centrifuge tube without disturbing the bottom layer that containing 5 ml of Ficoll-paque plus density gradient solution. The layered blood is centrifuged at 1500 x g for 30 minutes at room temperature. The middle thin layer containing PBMCs is carefully removed, transferred to another sterile centrifuge tube, and washed twice with PBS to remove Percoll. Isolated rat and human PBMCs are cultured in 10%fetal bovine serum/DMEM.
  • the rat and human PBMCs are treated with DMSO (control), compounds of the invention, or 17-DMAG at concentrations of 0, 1 , 5, 25, or 100 nM (in DMSO) for 16 hours.
  • DMSO control
  • compounds of the invention or 17-DMAG at concentrations of 0, 1 , 5, 25, or 100 nM (in DMSO) for 16 hours.
  • the cells are then collected and rinsed in ice-cold PBS and stored in liquid nitrogen until further analysis.
  • PBMC are prepared in Western lysis buffer (10 mmol/L HEPES, 42 mmol/L KCl, 5 mmol/L MgCl 2 , 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 1 mmol/L DTT, 1 % Triton X-100, freshly supplemented with Ix protease inhibitor cocktail from Pierce, Rockford, IL). Lysate protein concentrations are quantified by bicinchoninic acid assay (Pierce) and normalized. Equal amounts of protein are loaded onto 10 % NuPAGE Bis-Tris Gels (Invitrogen) and subsequently transferred onto polyvinylidene difluoride membranes. The membranes are blocked in 5% milk in TBST.
  • Western lysis buffer (10 mmol/L HEPES, 42 mmol/L KCl, 5 mmol/L MgCl 2 , 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 1
  • glucocorticod receptor from Santa Cruz Biotechnology, Inc. is added and incubated at room temperature for 1 hour with shaking. The blots are washed extensively in TBST before secondary antibodies are added for overnight incubation at 4°C with gentle shaking. The blots are again washed extensively and developed with SuperSignal West Femto substrate (Pierce). The immunoblot analysis is performed to measure the level of total GRs by Quantity One software from Bio-Rad.
  • Example 86 Suppression of Glucocorticoid Receptor Levels in Human PBMCs and Renal Cells, as well as in Several Human Cancer Cell Lines
  • the whole blood samples from healthy human volunteers are collected and the PBMCs are isolated immediately as described in Example 11. Isolated human PBMCs are cultured in 10%fetal bovine serum/DMEM.
  • Human PBMCs, kasumi- 1, Mv-4-11, HeIa, and human renal proximal tubule epithelial cells are treated with DMSO (control), compounds of the invention, 17- DMAG at concentrations of 0, 5, 25, or 100 nM (in DMSO) for 16 hours.
  • DMSO control
  • compounds of the invention 17- DMAG at concentrations of 0, 5, 25, or 100 nM (in DMSO) for 16 hours.
  • the cells are then collected and rinsed in ice-cold PBS and stored in liquid nitrogen until further analysis.
  • PBMC, renal and tumor cell pellets are prepared in Western lysis buffer (10 mmol/L HEPES, 42 mmol/L KCl, 5 mmol/L MgCl 2 , 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 1 mmol/L DTT, 1 % Triton X- 100, freshly supplemented with 1 x protease inhibitor cocktail from Pierce, Rockford, IL). Lysate protein concentrations are quantified by bicinchoninic acid assay (Pierce) and normalized. Equal amounts of protein are loaded onto 10 % NuPAGE Bis-Tris Gels (Invitrogen) and subsequently transferred onto polyvinylidene difluoride membranes.
  • Western lysis buffer (10 mmol/L HEPES, 42 mmol/L KCl, 5 mmol/L MgCl 2 , 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 1 mmol/L D
  • SD rats Male adult Sprague-Dawley (SD) rats, five per group, are randomly assigned into five testing groups which received treatments as shown in Table 3 :
  • test compounds are administered daily intravenously via tail vein for four days. All rats are sacrificed at the study day 5. About 1-2 mL of blood samples are collected per animal. The blood samples are then pulled together as a group for PBMC isolation. PBMCs are isolated and an immunoblot using an antibody that recognizes the glucocorticoid receptor is prepared, as described in Examples 85 and 86.
  • kDNA decatenation assay TopoGEN, Inc. Port Orange, FL.
  • Substrate kDNA is mixed with compounds (10, 100, or 500 ⁇ M) and incubated at 37 0 C for 30 min.
  • the reaction is stop by adding 1/5 volume of stop buffer.
  • 20 ⁇ l of the reaction is loaded on 1% agarose gel.
  • Image of decatenation of kDNA by compounds is taken by Kodak Image Station 440.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de triazole substitués et des compositions comprenant des composés de triazole substitués. L'invention concerne en outre des procédés pour inhiber l'activité de Hsp90 chez un sujet en ayant besoin, et des procédés pour prévenir ou pour traiter des troubles hyperprolifératifs, tels que le cancer, chez un sujet en ayant besoin. Lesdits procédés comprennent l'administration au sujet du composé de triazole substitué de l'invention ou d'une composition comprenant un tel composé.
PCT/US2008/002185 2007-02-20 2008-02-20 Composés de triazole modulant l'activité de hsp90 Ceased WO2008103353A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90235107P 2007-02-20 2007-02-20
US60/902,351 2007-02-20

Publications (1)

Publication Number Publication Date
WO2008103353A1 true WO2008103353A1 (fr) 2008-08-28

Family

ID=39445881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/002185 Ceased WO2008103353A1 (fr) 2007-02-20 2008-02-20 Composés de triazole modulant l'activité de hsp90

Country Status (2)

Country Link
TW (1) TW200904417A (fr)
WO (1) WO2008103353A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004132A1 (fr) 2009-07-10 2011-01-13 Sanofi-Aventis Nouveaux derives de l'indole inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011027081A2 (fr) 2009-09-03 2011-03-10 Sanofi-Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US8901308B2 (en) 2004-11-18 2014-12-02 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
US20150119395A1 (en) * 2012-04-04 2015-04-30 Synta Pharmaceuticals Corp. Novel triazole compounds that modulate hsp90 activity
CN113121505A (zh) * 2021-03-02 2021-07-16 中国人民解放军海军军医大学 一种具有抗真菌与抗肿瘤双重作用的三唑酮类化合物及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106349233B (zh) * 2015-07-15 2021-06-01 上海翰森生物医药科技有限公司 3,4-二苯基-4h-1,2,4-三唑衍生物及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055760A1 (fr) * 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Composes triazole modulant l'activite de hsp90
WO2006095783A1 (fr) * 2005-03-09 2006-09-14 Nippon Kayaku Kabushiki Kaisha Nouvel inhibiteur de hsp 90
WO2007139967A2 (fr) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Composés de triazole modulant l'activité de hsp90
WO2007139952A2 (fr) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Synthèse de composés triazole modulant l'activité hsp90
WO2008041610A1 (fr) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha Mélange d'un dérivé de résorcinol avec un polymère
WO2008057246A2 (fr) * 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Procédé de traitement de troubles inflammatoires

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055760A1 (fr) * 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Composes triazole modulant l'activite de hsp90
WO2006095783A1 (fr) * 2005-03-09 2006-09-14 Nippon Kayaku Kabushiki Kaisha Nouvel inhibiteur de hsp 90
WO2007139967A2 (fr) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Composés de triazole modulant l'activité de hsp90
WO2007139952A2 (fr) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Synthèse de composés triazole modulant l'activité hsp90
WO2008041610A1 (fr) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha Mélange d'un dérivé de résorcinol avec un polymère
WO2008057246A2 (fr) * 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Procédé de traitement de troubles inflammatoires

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8901308B2 (en) 2004-11-18 2014-12-02 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
US9090569B2 (en) 2004-11-18 2015-07-28 Synta Pharmaceuticals Corp. Triazone compounds that modulate HSP90 activity
WO2011004132A1 (fr) 2009-07-10 2011-01-13 Sanofi-Aventis Nouveaux derives de l'indole inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011027081A2 (fr) 2009-09-03 2011-03-10 Sanofi-Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US20150119395A1 (en) * 2012-04-04 2015-04-30 Synta Pharmaceuticals Corp. Novel triazole compounds that modulate hsp90 activity
CN113121505A (zh) * 2021-03-02 2021-07-16 中国人民解放军海军军医大学 一种具有抗真菌与抗肿瘤双重作用的三唑酮类化合物及应用
CN113121505B (zh) * 2021-03-02 2023-03-07 中国人民解放军海军军医大学 一种具有抗真菌与抗肿瘤双重作用的三唑酮类化合物及应用

Also Published As

Publication number Publication date
TW200904417A (en) 2009-02-01

Similar Documents

Publication Publication Date Title
EP2118077B1 (fr) Composés à base de triazole modulant l'activité de hsp90
EP2155694B1 (fr) Derives de triazinone et de diazinone utiles comme inhibiteurs de hsp90
US9120745B2 (en) Triazole compounds that modualte HSP90 activity
US8927548B2 (en) Triazole compounds that modulate HSP90 activity
EP2035396B1 (fr) Composés de triazole modulant l'activité de hsp90
EP2038262B1 (fr) Composés de triazole qui modulent l'activité de la hsp90
EP1928846B1 (fr) Dérivés de triazole modulant l'activité de hsp90
WO2009148599A1 (fr) Composés de pyrrole qui modulent l’activité de la hsp90
WO2008103353A1 (fr) Composés de triazole modulant l'activité de hsp90
HK1137455B (en) Triazole compounds that modulate hsp90 activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08725782

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08725782

Country of ref document: EP

Kind code of ref document: A1